Loading...
Freedom of Information (FOI) NHS Lothian | Our Organisation
NOTE: 100 recent requests are displayed below. Use search to find older requests.
Freedom of Information Request Reference: 12178
Date Received: 10/11/2026
Summary:
Request in relation to information governance.
Date of Response: 10/11/2026
View Response: 12178-1.pdf

Freedom of Information Request Reference: 12135
Date Received: 30/10/2026
Summary:
I would be grateful if you could provide the following information regarding major colorectal and abdominal surgical activity undertaken within the Trust during the three financial years 2023/24, 2024/25 and 2025/26. I am seeking aggregated activity data only and do not require any patient-identifiable information. 1. Major colorectal resections For each financial year, please provide the number of the following procedures performed: • Right hemicolectomy • Extended right hemicolectomy • Left hemicolectomy • Sigmoid colectomy • Anterior/high anterior resection • Low anterior resection • Abdominoperineal resection • Hartmann's procedure • Hartmann's reversal • Subtotal colectomy • Total colectomy • Proctocolectomy • Other major colorectal resections, if recorded separately Where the information is held, please break down each procedure by surgical approach: • Open • Laparoscopic • Robotic • Laparoscopic converted to open • Robotic converted to open • Other/unknown 2. Elective and emergency activity Where available, please further identify whether these procedures were recorded as: • Elective • Emergency/non-elective 3. Surgical indication Where indication or diagnosis is held in an electronically reportable format, please provide a breakdown of major colorectal resections according to: • Colorectal cancer • Diverticular disease • Inflammatory bowel disease • Bowel obstruction • Bowel perforation • Bowel ischaemia • Other malignant disease • Other benign disease I appreciate that indication may be captured through diagnostic coding rather than a specific surgical indication field. If so, a breakdown according to the diagnostic categories/codes routinely used by the Trust would be appreciated. 4. Conversion to open surgery For each financial year, please provide: • Number of laparoscopic colorectal resections converted to open surgery • Number of robotic colorectal resections converted to open surgery If the reason for conversion is held within an existing electronically searchable/reportable field, please also provide the available breakdown by reason for conversion. I am not requesting manual review of individual patient records or operative notes to establish reasons for conversion. 5. Hospital/site Where the Trust provides major colorectal across more than one hospital site, please provide the above activity by hospital site, where this information is available.
Date of Response: 19/11/2026
View Response: 12135.pdf

Freedom of Information Request Reference: 12125
Date Received: 30/10/2026
Summary:
Since 2021, what assessments have been made of whether the transport and accommodation provision paid for by the health board and used by patients and their families are more likely to belong to groups that face difficulties or deprivation? For example, an assessment of provision based on disability status, working status, SIMD, income level, etc. If such assessments exist, please include these in the response to this query.
Date of Response: 19/11/2026
View Response: 12125.pdf

Freedom of Information Request Reference: 12115
Date Received: 28/10/2026
Summary:
1. Among all the children and young people from your health board area who waited in excess of the 18-week psychological therapies standard and started their treatment in (a) 2024/25 (b) 2025/26 (c) 2024-25 and (d) 2026/27 to date (including those still waiting), what was the total number of days over the 18-week standard that they collectively waited. Please break down the figures for each year specified. For example, if a person began their treatment after 30 weeks, then that person would contribute 84 days towards the total for the year in which they started their treatment (12 weeks x 7 days)
Date of Response: 19/11/2026
View Response: 12115.pdf

Freedom of Information Request Reference: 12110
Date Received: 28/10/2026
Summary:
I would like to have an update of figures that your Board provided to FOI request 8328 about PSA tests. 1. The total number of PSA tests requested 2. The number requested from Primary Care 3. The number requested by Secondary Care. Can you give the number from 2024 to 30 June 2026, please?
Date of Response: 19/11/2026
View Response: 12110.pdf

Freedom of Information Request Reference: 12105
Date Received: 27/10/2026
Summary:
1. List of titles of each occupation/job currently employed within Health Board on Agenda for Change Terms and Conditions 2. For each occupation/job the total number of posts employed 3. For each occupation/job which Agenda for Change grade/s these posts are employed on
Date of Response: 19/11/2026
View Response: 12105.pdf

Freedom of Information Request Reference: 12100
Date Received: 27/10/2026
Summary:
How many babies were born with neonatal abstinence syndrome in your health board area in (a) 2025/25 b) 2026/27 to date.
Date of Response: 19/11/2026
View Response: 12100.pdf

Freedom of Information Request Reference: 12095
Date Received: 23/10/2026
Summary:
How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: •Atezolizumab (Tecentriq) •Durvalumab (Imfinzi) •Nivolumab (Opdivo) •Pembrolizumab (Keytruda) •Chemotherapy •Radiotherapy •Chemotherapy AND Radiotherapy •Osimertinib
Date of Response: 19/11/2026
View Response: 12095.pdf

Freedom of Information Request Reference: 12092
Date Received: 22/10/2026
Summary:
I would be grateful if you could provide the following information regarding the provision of hybrid mail, print and post, patient correspondence or mailing services used by the Health Board. 1. Who is the current supplier(s) for hybrid mail, print and post, or patient communication services used by the Health Board? 2. Is this service provided under: o A Health Board-wide patient communications, hybrid mail, print and post, or managed print contract? o Can you confirm what Patient Admin System(s) you use - do these integrate with Hybrid Mail 3. Please provide: o Contract title o Supplier name o Contract start date o Contract expiry date o Any extension options and associated dates o Estimated annual contract value (if available) o Can you please provide the contact names & email addresses for the Managers responsible for Hybrid Mail o Who looks after Hybrid Mail in Procurement 4. Which procurement route was used? o Framework (please specify framework name) o Open tender o Direct award o Other (please specify)
Date of Response: 19/11/2026
View Response: 12092.pdf

Freedom of Information Request Reference: 12091
Date Received: 22/10/2026
Summary:
Please provide the following information for all clinical insourcing contracts active between 1 October 2025 and 30 September 2026, including those that have since expired. 1. Provider names: The names of all private companies contracted to deliver clinical insourcing services within your organisation. 2. Clinical specialties and services: The specialties and types of clinics, procedures or services delivered by each provider (e.g. Dermatology, Neurology, Endoscopy, Radiology, outpatient clinics, diagnostic procedures, etc.). 3. Contract costs: The total contract value and actual expenditure for each provider, ideally broken down by specialty where this information is held as well as cost per clinic or per day if specified in the contract. 4. Contract dates: The commencement and expiry dates of each contract, including any agreed extensions or remaining extension options.
Date of Response: 20/11/2026
View Response: 12091.pdf

Freedom of Information Request Reference: 12090
Date Received: 22/10/2026
Summary:
1. How many patients have currently started and are undergoing assessment for Autism Spectrum Disorder under CAMHS? 2. How many patients have currently started and are undergoing assessment for ADHD under CAMHS? 3. How many Autism Spectrum Disorder diagnosis have been given in CAMHS in the 12 months prior to 30th September 2026? 4. How many ADHD diagnoses have been given in CAMHS in the 12 months prior to 30th September 2026? 5. How many patients are currently on the waiting list for intake to CAMHS for the Neurodevelopmental Assessment list? 6. Is the Neurodevelopment waiting list at CAMHS currently accepting new patients? 7. How many patients have undertaken an initial intake or choice appointment and are now on the waiting list for Neurodevelopmental assessment? 8. How long is the current wait from intake appointment to Neurodevelopmental assessment? For example Edinburgh South CAMHS are currently starting to see patients for Neurodevelopmental assessment who joined the waiting list in November 2021 following an intake appointment (correct as of September 2026) 9. Following ADHD Assessment, how long is the wait to see a professional to discuss and receive medication for ADHD?
Date of Response: 19/11/2026
View Response: 12090.pdf

Freedom of Information Request Reference: 12089
Date Received: 21/10/2026
Summary:
Please would provide a breakdown of all expenditure actually incurred in developing the proposed replacement East Calder Health Centre from 2016 to the present date. In particular, please identify expenditure on business-case preparation, architectural and engineering design, HubCo and other consultants, surveys, quantity surveying, options appraisal, community consultation, legal and land-related work, and project management. For each category, please provide the amount paid, the date or financial year of payment, the recipient organisation and the source of funding. Please distinguish expenditure actually incurred from budgeted or estimated costs and unpaid commitments. Please also confirm whether any work or design commissioned for the project has been written off, abandoned or requires repetition, and the value of any such expenditure where known. Finally, please clarify the status of the £400,000 requested from the Scottish Government in September 2023 for further design work, including whether any portion was subsequently authorised or spent. I would welcome the total expenditure incurred to date, together with any available breakdown, rather than estimates of the eventual construction cost.
Date of Response: 20/11/2026
View Response: 12089.pdf

Freedom of Information Request Reference: 12085
Date Received: 21/10/2026
Summary:
Please provide the following information for each Type 1 emergency department operated by the board. For each month from 1 January 2025 to 30 September 2026, please provide: 1. The number of A&E attendances where the patient spent: o more than 24 hours; o more than 36 hours; o more than 48 hours in the emergency department. 2. The longest recorded A&E stay during 2026 to date, broken down by hospital. 3. Please confirm whether the board centrally records or collates the number of patients receiving care in hospital corridors or other areas not ordinarily designated for patient care because normal clinical capacity was unavailable. 4. If so, please provide the number of patients recorded as receiving such care, broken down by month and hospital, from 1 January 2025 to 30 September 2026.
Date of Response: 16/11/2026
View Response: 12085.pdf

Freedom of Information Request Reference: 12083
Date Received: 21/10/2026
Summary:
• Total spend on clinical insourcing between April 2026 until present • Breakdown of the specialties this was used in and including grade/band of clinician • Please confirm what framework this was supplied under i.e. SBS Insourcing/Workforce Alliance/HTE • Total spend on clinical Outsourcing between April 2026 until present • Breakdown of the names of the companies the work was outsourced and the specialties this was used in
Date of Response: 20/11/2026
View Response: 12083.pdf

Freedom of Information Request Reference: 12082
Date Received: 21/10/2026
Summary:
I am requesting the following information held by NHS Lothian: • The number of children admitted to hospital for treatment of malnutrition in each quarter since 1 January 2026, broken down as: o Q1: 1 January – 31 March 2026 o Q2: 1 April – 30 June 2026 o Q3: 1 July – 30 September 2026 o Q4 (part): 1 October 2026 – the date of this request • The number of children admitted to hospital for treatment of malnutrition between 22 December 2025 and 5 January 2026 inclusive. For both questions, please give the number of individual patients and the total number of admissions.
Date of Response: 20/11/2026
View Response: 12082.pdf

Freedom of Information Request Reference: 12079
Date Received: 20/10/2026
Summary:
Please provide the following information. 1. Annual totals of incidents For each calendar year from 1 January 2018 to the date of this request in 2026, please provide the total number of recorded incidents of violence and aggression perpetrated by patients against staff working in Emergency Departments. Please provide one annual total for each year, covering the following periods: • 2018: 1 January – 31 December 2018 • 2019: 1 January – 31 December 2019 • 2020: 1 January – 31 December 2020 • 2021: 1 January – 31 December 2021 • 2022: 1 January – 31 December 2022 • 2023: 1 January – 31 December 2023 • 2024: 1 January – 31 December 2024 • 2025: 1 January – 31 December 2025 • 2026: 1 January – the date on which this request is received or processed, using the latest available data. • Please note the following requirements regarding the data provided: 1. Annual totals only: Please provide one total figure per calendar year. We are not requesting monthly figures, quarterly figures, or any other breakdown by reporting period. 2. Single aggregate figure: Please provide the total number of incidents for each year, without splitting the figures into categories, subcategories or types of violence or aggression. For example, please do not provide separate figures for physical assault, verbal abuse, threats, or other forms of violence and aggression. 3. Patient-to-staff incidents only: Include only incidents in which a patient was the perpetrator and a member of ED staff was the victim. Exclude incidents involving staff against patients, staff against other staff, visitors against staff, visitors against patients, or any other perpetrator–victim combination. 4. Type-1 Emergency Departments only: Include incidents occurring within type-1 Emergency Departments. Exclude incidents occurring in other hospital departments or services, unless those incidents are recorded as occurring within an Emergency Department. 5. Consistent reporting: Please use the same incident definition and reporting methodology across the years wherever possible. If the definition, recording system or methodology has changed during the period, please explain this under section 2 below. Where your organisation is responsible for multiple hospitals or Emergency Departments, please provide a single aggregate annual total covering all relevant EDs within your organisation. Do not provide separate figures for individual hospitals or departments. 2. Missing data and reporting coverage For every calendar year in which a figure cannot be provided, or in which the figure does not cover the full reporting period, please explain the reason. Specifically, please: 1. Identify missing annual totals: State which years, if any, do not have a recorded annual total for patient-to-staff violence and aggression in Emergency Departments. 2. Explain why data is unavailable: For each missing annual total, explain why the information is not available. For example, clarify whether the relevant incidents were not recorded, the data was not retained, the reporting system was not in place, or the information cannot be retrieved from existing records. 3. Identify incomplete months: Where an annual total covers fewer than 12 months, identify the specific months for which data is missing or unavailable. For example, if a figure for 2022 covers January to September only, please state that October, November and December are missing. 4. Clarify partial-year figures: Where an annual total covers only part of a year, provide the total for the available period and identify the months covered and the months missing. Please do not substitute a blank, zero or an estimate for a partial-year total without explaining the position. 5. Explain changes in recording: Identify any changes to incident reporting systems, definitions, recording practices or data coverage during 2018–2026 that materially affect the comparability of annual totals. A missing annual total must be distinguished from a recorded total of zero incidents. If no incidents were recorded, please confirm whether this represents a genuine recorded total of zero or whether the absence of a figure reflects missing or unavailable data.
Date of Response: 17/11/2026
View Response: 12079.pdf

Freedom of Information Request Reference: 12078
Date Received: 19/10/2026
Summary:
In Q3 2026, the 3 months (July - September 2026), how many haemophilia A and B and von Willebrand patients were treated with the following coagulation factors in your trust and how much volume (IUs or mg) was used? Hemlibra (non-inhibitor patients) Hemgenix Altuvoct Advate Adynovi Elocta Esperoct NovoEight ReFacto AF Nuwiq Hympavzi Idelvion Refixia Alprolix BeneFIX Replenine Rixubis Veyvondi Voncento Wilate Willfact
Date of Response: 16/11/2026
View Response: 12078.pdf

Freedom of Information Request Reference: 12077
Date Received: 19/10/2026
Summary:
I would like to request the following information for Q3 2026 (July–September 2026). Please provide total volume (IU/mg) and, where available, total number of patients treated with the following products: • NovoSeven (eptacog alfa) • Cevenfacta (eptacog beta) • FEIBA (anti-inhibitor coagulant complex) • Obizur (susoctocog alfa) • Hemlibra (emicizumab) (haemophilia A inhibitor patients only) Where feasible from existing records, I would also welcome any available breakdown of the above patient numbers and/or volumes by indication. For example: • haemophilia A with inhibitors • haemophilia B with inhibitors • Acquired haemophilia (AHA) • Glanzmann thrombasthenia • Factor VII deficiency • other (please specify)
Date of Response: 16/11/2026
View Response: 12077.pdf

Freedom of Information Request Reference: 12075
Date Received: 19/10/2026
Summary:
Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of July 2026 and the end of September 2026, or latest 3-month period available? 1.1 Abemaciclib (Verzenios) 1.2 Alpelisib (Piqray) 1.3 Camizestrant (Etcamah) 1.4 Capivasertib (Truqap) 1.5 Elacestrant (Orserdu) 1.6 Elinzanetant (Lynkuet) 1.7 Fulvestrant (fulvestrant or Faslodex) 1.8 Inavolisib (Inaqovi) 1.9 Imlunestrant (Inluriyo) 1.10 Olaparib (Lynparza) 1.11 Palbociclib (Ibrance) 1.12 Ribociclib (Kisqali) 1.13 Talazoparib (Talzenna) 1.14 Vepdegestrant (Veppanu) Q2. How many patients were treated in total, regardless of diagnosis, with the following products in the 3 months between 1st July 2026 and the end of September 2026, or latest 3-months for which data are available? 2.1 Pertuzumab (Perjeta) 2.2 Pertuzumab with Trastuzumab (Phesgo) 2.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) 2.4 Trastuzumab Deruxtecan (Enhertu) 2.5 Trastuzumab Emtansine (Kadcyla) 2.6 Tucatinib (Tukysa) 2.7 Neratinib (Nerlynx) Q3. How many patients were treated specifically for breast cancer (ICD-10 codes = C50*, D05) in the 3 months between 1st July 2026 and the end of September 2026? 3.1 Olaparib - All types of breast cancer 3.2 Talazoparib – All types of breast cancer 3.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) - All types of breast cancer 3.4 Trastuzumab Deruxtecan (Enhertu) - All types of breast cancer Q4. How many patients received the following medicines with curative treatment intent in the 3 months between 1st July 2026 and the end of September 2026, or latest 3-month period for which data are available? 4.1 Abemaciclib (Verzenios) 4.2 Ribociclib (Kisqali) 4.3 Pertuzumab (Perjeta) 4.4 Pertuzumab with Trastuzumab (Phesgo) 4.5 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, Trastuzumab) 4.6 Trastuzumab Emtansine (Kadcyla) Q5. How many patients received the following products as part of neoadjuvant or adjuvant therapy in the 3 months between 1st July 2026 and the end of September 2026, or latest 3-month period for which data are available? 5.1 Olaparib (Lynparza) 5.2 Pertuzumab (Perjeta) 5.3 Pertuzumab with Trastuzumab (Phesgo) 5.4 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) 5.5 Trastuzumab Emtansine (Kadcyla) Q6. How many patients received trastuzumab deruxtecan (Enhertu) for the following types of breast cancer in the 3 months between 1st July 2026 and the end of September 2026, or latest 3-month period for which data are available? 6.1 HER2+ve Breast Cancer 6.2 HER2-low Breast Cancer Q7. How many patients were treated with the following medicines in combination in the 3 months between 1st July 2026 and the end of September 2026, or latest 3-month period available? 7.1 Pertuzumab + Trastuzumab (Phesgo) + Taxane (Docetaxel or Paclitaxel) 7.2 Pertuzumab (Perjeta) + Trastuzumab Deruxtecan (Enhertu) Q8. How many submissions for funding were made to the Cancer Drugs Fund for trastuzumab deruxtecan (Enhertu) with the following BlueTeq codes in the 3 months between 1st July 2026 and the end of September 2026, or latest 3-month period available? TRAD1 TRAD2 TRAD3
Date of Response: 16/11/2026
View Response: 12075.pdf

Freedom of Information Request Reference: 12074
Date Received: 19/10/2026
Summary:
Among all the children and young people from your health board area who waited in excess of the 18- week CAMHS standard and started their treatment in (a) 2025-26 and (b) 2026-27 to date (including those still waiting). What was the total number of days over the 18-week standard that they collectively waited. Please break down the figures for each year specified.
Date of Response: 16/11/2026
View Response: 12074.pdf

Freedom of Information Request Reference: 12073
Date Received: 19/10/2026
Summary:
Please provide the total number of complaints received by the Health Board concerning waiting times for Child and Adolescent Mental Health Services (CAMHS) during: a. The financial year 2025–2026 (1 April 2025 to 31 March 2026). b. The period from 1 April 2026 to the date of this request. Please include complaints submitted by individuals on their own behalf, as well as complaints submitted by individuals or organisations on behalf of a patient. Where possible, please break down the figures by financial year and indicate the number of complaints submitted by individuals directly and by representatives or organisations on behalf of a patient.
Date of Response: 20/11/2026
View Response: 12073.pdf

Freedom of Information Request Reference: 12072
Date Received: 19/10/2026
Summary:
Please provide the following information for the period of the last 12 months (or the most recent 12-month period for which data is available): We do not use those suppliers to purchase materials 1. The total spend on electrical materials with each of the following suppliers: • Edmundson Electrical • Rexel • City Electrical Factors (CEF) • RS Components 2. If you have a Hard FM maintenance team on site could you please advise who.
Date of Response: 16/11/2026
View Response: 12072.pdf

Freedom of Information Request Reference: 12071
Date Received: 19/10/2026
Summary:
The number of complaints about the palliative care team and the number of complaints about care in the Lochranza Ward in the Royal Hospital For Children and Young People between 15 October 2023 and 15 October 2026. Could I get this information broken down by month and whether or not they were upheld.
Date of Response: 16/11/2026
View Response: 12071.pdf

Freedom of Information Request Reference: 12070
Date Received: 19/10/2026
Summary:
Sourced Staffing Arrangements 1a. Do you have a master vendor (MV) or neutral vendor (NV) arrangement in place for sourcing agency staff? If so, please state which arrangement is in place 1b. What is the name of the MV/NV provider(s) and what staffing groups do they source? e.g. medical, nursing etc.                                                                                                                 1c. As part of the arrangement, is any NV technology provided by the supplier to help manage the procurement of agency staff?                                                                1d. Please provide the contract start and end date for the supplier (dd/mm/yy)                                                                                    Direct Engagement 2a. Does the organisation use a third party to provide a Direct Engagement/Outsourced Employment Solution*?                                                  2b. What is the name of the Direct Engagement (DE)/Outsourced Employment supplier**                                                                       2c. Under the DE/Outsourced Employment arrangement, which staffing groups are managed? For example; Medical, Admin, Scientific staff. Please list all applicable                  2d. Please provide the contract start and end date for the DE supplier (dd/mm/yy) 2e. How much did the organisation pay the supplier in 25/26 (April 2025 to March 2026) for the provision of the direct engagement service?   2f. What type of Direct Engagement contract is in place between the trust and the worker?  E.g. Fixed term, casual, zero hours etc.  2g. Are workers issued a P45 at the end of their assignment? 2h. Does your DE provider process DE payroll? 2i. If not, who is responsible for processing DE payroll? 2j. Who is responsible for inputting timesheet data into your DE solution?  2k. Who is responsible for inputting workers' bank details into the DE solution? Bank Management 3a. Please name the technology provider used to manage the supply of your bank staff, inclusive of any outsourced or managed arrangements *** If more than one supplier is used, please name all suppliers 3b. Please name the staffing group each provider is used for e.g. medical, nursing, AHPs, admin and clerical 3c. Please provide the contract start and end date for each bank supplier (dd/mm/yy) 3d. How much did the organisation pay the supplier(s) in 25/26 for the provision of the bank service?
Date of Response: 16/11/2026
View Response: 12070.pdf

Freedom of Information Request Reference: 12069
Date Received: 19/10/2026
Summary:
1. Please provide details of the number of days of nursing and midwifery staff time lost due to absence relating to mental ill health in 2025/26. Please provide this data broken down by: (a) nursing staff days lost (b) midwifery staff days lost (c) overall total days
Date of Response: 16/11/2026
View Response: 12069.pdf

Freedom of Information Request Reference: 12067
Date Received: 19/10/2026
Summary:
please provide the following information about consultant posts in Emergency Medicine (including Paediatric Emergency Medicine, if your Health Board appoints to these separately). In order of priority: 1. Current offer For the most recently advertised substantive EM consultant post, please state the total number of Programmed Activities (PAs) offered and how these were split between Direct Clinical Care (DCC) and Supporting Professional Activities (SPA). 2. Advertised PA split, 2021/22 to 2025/26 For each financial year from 2021/22 to 2025/26, please state the DCC/SPA split given in the job advert or job description for substantive EM consultant posts. If the split was the same for all posts in a year, a single figure is fine. Copies of the job descriptions or adverts would also be acceptable in place of extracted figures. 3. Number of appointments, 2021/22 to 2025/26 For each financial year from 2021/22 to 2025/26, please state the number of EM consultant appointments made, reporting substantive posts and Health Board-employed locum consultant posts separately. Agency and bank locums are excluded. If any figure is fewer than five and you consider it identifiable, please report it as "fewer than five" rather than withholding it.
Date of Response: 16/11/2026
View Response: 12067.pdf

Freedom of Information Request Reference: 12066
Date Received: 19/10/2026
Summary:
The number of children (i.e. under 18 years old) who have had a tooth extracted due to tooth decay under general anaesthetic in hospital. Please provide this for the calendar years 2022, 2023, 2024, 2025 and 2026 to date. The number of children admitted to hospital due to tooth decay. Please provide this for the calendar years as above.
Date of Response: 16/11/2026
View Response: 12066.pdf

Freedom of Information Request Reference: 12065
Date Received: 16/10/2026
Summary:
Q1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available? 1.1 Abiraterone (Zytiga or generic abiraterone) 1.2 Apalutamide (Erleada) 1.3 Cabazitaxel 1.4 Darolutamide (Nubeqa) 1.5 Docetaxel 1.6 Enzalutamide (Xtandi) 1.7 Lutetium-177 PSMA-617 (Pluvicto) 1.8 Olaparib (Lynparza) 1.9 Relugolix (Orgovyx, Ryeqo) 1.10 Talazoparib (Talzenna) Q2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available? 2.1 Docetaxel for prostate cancer 2.2 Olaparib (Lynparza) for prostate cancer 2.3 Talazoparib (Talzenna) for prostate cancer 2.4 Relugolix (Orgovyx) for prostate cancer Q3. How many patients received their first cycle or first dose of the following products in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? 3.1 Abiraterone (Zytiga or generic abiraterone) 3.2 Apalutamide (Erleada) 3.3 Cabazitaxel (Jevtana or generic cabazitaxel) 3.4 Darolutamide (Nubeqa) 3.5 Enzalutamide (Xtandi) Q4. How many patients were treated with the following combinations in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available? Please give total number of patients and number of patients receiving their first dose or first cycle. 4.1 Darolutamide (Nubeqa) + Docetaxel 4.2 Darolutamide (Nubeqa) monotherapy 4.3 Olaparib (Lynparza) + Abiraterone Q5. How many patients were switched from the following products to darolutamide (Nubeqa) in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available? 5.1 Abiraterone 5.2 Apalutamide 5.3 Enzalutamide Q6. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available? 6.1 Abiraterone 6.2 Enzalutamide Q7. How many patients were treated with darolutamide (Nubeqa) for the following indications and BlueTeq CDF codes between July 2026 to the end of September 2026? DARO1 DARO2 DARO3 Q8. How many patients received Cemiplimab (Libtayo) for Non-small Cell Lung Cancer in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available? 8.1 Cemiplimab (Libtayo) for Non-small Cell Lung Cancer Q9. How many patients received Cemiplimab (Libtayo) for Non-small Cell Lung Cancer in combination or as monotherapy in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available? 9.1 Cemiplimab + Cisplatin or Carboplatin chemotherapy 9.2 Cemiplimab monotherapy Q10. How many patients received the following products in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available? 10.1 Amivantamab (Rybrevant) 10.2 Lazertinib (Lazcluze) 10.3 Osimertinib (Tagrisso) Q11. How many patients received the following products in combination or as monotherapy in the 3 months between July 2026 to the end of September 2026? 11.1 Amivantamab + Lazertinib 11.2 Amivantamab + Carboplatin + Pemetrexed 11.3 Amivantamab Monotherapy 11.4 Osimertinib + Pemetrexed + Platinum Chemotherapy 11.5 Osimertinib Monotherapy Q12. How many patients received Osimertinib (Tagrisso) as Adjuvant treatment in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available? 12.1 Osimertinib as adjuvant treatment
Date of Response: 16/11/2026
View Response: 12065.pdf

Freedom of Information Request Reference: 12064
Date Received: 16/10/2026
Summary:
On how many occasions were children hospitalised for (a) alcohol-related, or (b) drug-related injuries or illnesses in (i) 2019-20, (ii) 2021-21, (iii) 2021-22, (iv) 2022-23, (v) 2023-24), (vi) 2024-25 and (vii) 2025-26, broken down by (A) 0-4 years olds, (B) 5-9 year olds, (C) 10-13 year olds, (D) 14-17 year olds. If an incident was related to both drugs and alcohol, and is therefore included in both categories, please provide details of on how many occasions this occurred, broken down by year and age category. Please include: • both attendances at an emergency department and admissions to hospital • those admitted for observation • cases of accidental consumption
Date of Response: 16/11/2026
View Response: 12064.pdf

Freedom of Information Request Reference: 12062
Date Received: 16/10/2026
Summary:
Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in between the start of July 2026 to the end of September 2026, or latest 3-month period available? 1.1 Acalabrutinib (Calquence) 1.2 Ibrutinib (Imbruvica) 1.3 Pirtobrutinib (Jaypirca) 1.4 Venetoclax (Venclyxto) 1.5 Zanubrutinib (Brukinsa) 1.6 Rituximab 1.7 Obinutuzumab (Gazyvaro) Q2. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma – ICD10 codes = C911, C91.1 OR C830, C83.0 - were treated with the following medicines in the 3 months between the start of July 2026 to the end of September 2026, or latest 3-month period available? 2.1 Acalabrutinib (Calquence) 2.2 Ibrutinib (Imbruvica) 2.3 Pirtobrutinib (Jaypirca) 2.4 Venetoclax (Venclyxto) 2.5 Zanubrutinib (Brukinsa) 2.6 Obinutuzumab (Gazyvaro) 2.7 Rituximab Q3. How many patients with Mantle Cell Lymphoma (ICD-10 code = C83.1) were treated with the following medicines, in the 3 months between the start of July 2026 to the end of September 2026? 3.1 Acalabrutinib 3.2 Ibrutinib 3.3 Zanubrutinib 3.4 Pirtobrutinib 3.5 Bortezomib 3.6 Lenalidomide 3.7 Brexucabtagene Autoleucel (Tecartus) 3.8 Lisocabtagene Maraleucel (Breyanzi) Q4. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma were treated with the following medicines in combination or as monotherapy in the 3 months between 1st July 2026 to the end of September 2026, or latest 3-month period available? 4.1 Ibrutinib + Venetoclax 4.2 Obinutuzumab + Venetoclax 4.3 Acalabrutinib + Venetoclax Q5. How many patients with Acalabrutinib in combination with Rituximab + Bendamustine between 1st July 2026 to the end of September 2026, or latest 3-month period available?
Date of Response: 16/11/2026
View Response: 12062.pdf

Freedom of Information Request Reference: 12060
Date Received: 14/10/2026
Summary:
Medical workforce. At 30th September 2026, please state the number of whole time equivalent (WTE) consultants employed by the authority: 1. WTE Histopathology Consultants 2. WTE Radiology Consultants Histopathology reporting. For the 6 month period 1st April 2026 to 30th September 2026, please state the following in relation to histopathology activity undertaken by the authority: 3. How many histopathology cases were reported during the period Of these: 4. How many were reported by consultants employed by the authority during their salaried programmed activities (PAs) 5. How many were reported by consultants employed by the authority (or partnerships of such consultants) outside their contracted PAs for additional payment above their salary 6. How many were reported by locum pathologists, biomedical scientists, and or medical staff below consultant grade 7. How many were reported by external companies 8. Please break down the amount in question 7, and state how many were reported by each of the following companies a. Backlogs (part of HCA) b. Source Bioscience c. Cellular Pathology Services d. Unilabs e. Diagnexia f. Medica g. Poundbury Cancer Institute h. Digital Pathology Partners i. Other (please state which) Radiology Reporting. For the 6 month period 1st April 2026 to 30th September 2026, please state the following in relation to radiology activity undertaken by the authority: 9. How many radiology cases were reported during the period Of these: 10. How many were in each of the following modalities: a. Plain film/ x-ray b. MRI scan c. CT Scan d. PET CT/ SPECT 11. How many were reported by radiology consultants employed by the authority during their salaried programmed activities (PAs) 12. How many were reported by consultants employed by the authority (or partnerships of such consultants) outside their contracted PAs for additional payment above their salary 13. How many were reported by locum radiologists, medical staff below consultant grade, and or radiographers 14. How many were reported by external companies 15. Please break down the amount in question 14, and state how many were reported by each of the following companies a. Medica b. Everlight Radiology c. Telemedicine Clinic (TMC, part of Unilabs) d. 4Ways e. Dulwich Medical f. Hexarad e. Other (please state which)
Date of Response: 16/11/2026
View Response: 12060.pdf

Freedom of Information Request Reference: 12057
Date Received: 15/10/2026
Summary:
1. Contract Register Extract Please provide the most complete and current extract of your organisation’s contract register or equivalent system, as it exists on the date this request is processed or the date of the decision to release the data. We have already reviewed the contract register published on your organisation’s website, but we do not believe this represents the complete, unedited contract dataset held by your organisation. This request relates to existing recorded information only. I am not asking for new information to be created, nor for missing fields to be populated. In most cases, this will be a straightforward system export (e.g., from a contract management system or spreadsheet). Where available, the register should include (but is not limited to) the following fields: Contract Title, Supplier Name, Estimated Spend (annual or total), Contract Duration and Total Term (including extensions), Contract Start and Expiry Dates, Review Date, Contract Description, Contract Owner (role or name, as held in the system), Managing Department, Award Date, Procurement Category, Framework or Tender Reference, Participating Organisations, Central Purchasing Body, and Classification Codes (e.g., CPV). Please do not spend time amending, enriching, or redacting fields that are not readily available. I am content to receive the register in its raw exported form, exactly as held. 2. Website Publication & Data Disparity While we have reviewed the contract register currently published on your website, we require the full raw contracts register from your internal systems. If your response directs me back to the online portal, please confirm that the accessible dataset is fully up to date as of the date this request is processed or the decision to release the data is made. 3. Completeness & Redactions Please confirm whether the register provided constitutes the full, unedited dataset. If any information, columns, or specific fields have been removed or withheld from sharing, please simply list the headings of the data columns that are missing from the provided register. If spend values are withheld, please note this request seeks indicative or total contract values only, not detailed financial breakdowns. 4. System Capabilities If your organisation uses a specific contract management system, please confirm the name of the software or platform currently in use.
Date of Response: 20/11/2026
View Response: 12057.pdf

Freedom of Information Request Reference: 12056
Date Received: 15/10/2026
Summary:
Q1. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage): •Cobimetinib •Dabrafenib •Dabrafenib + Trametinib •Dacarbazine •Denosumab •Encorafenib + Binimetinib •Ipilimumab monotherapy •Ipilimumab + Nivolumab •Nivolumab monotherapy •Nivolumab + Relatlimab •Pembrolizumab •Pembrolizumab injection (Subcutaneous) •Trametinib •Vemurafenib •Vemurafenib + Cobimetinib •Other active systemic anti-cancer therapy •Palliative care only Q2. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY: •Ipilimumab monotherapy •Ipilimumab + Nivolumab •Nivolumab monotherapy •Nivolumab + Relatlimab •Pembrolizumab •Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib) •Other active systemic anti-cancer therapy •Palliative care only Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for melanoma? •Ipilimumab (monotherapy) •Nivolumab (monotherapy) •Nivolumab AND Ipilimumab (combination) •Nivolumab AND Relatlimab •Pembrolizumab •Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib) •Other active systemic anti-cancer therapy
Date of Response: 16/11/2026
View Response: 12056.pdf

Freedom of Information Request Reference: 12054
Date Received: 15/10/2026
Summary:
I would be grateful if you could respond with the number of patients treated with specific medicines between the start of July 2026 and the end of September 2026, or the latest three-month period for which data is available. Please include data for all hospitals in your organisation. Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of July 2026 and the end of September 2026? 1.1 Benralizumab (Fasenra) 1.2 Depemokimab (Exdensur) 1.3 Dupilumab (Dupixent) 1.4 Lebrikizumab (Ebglyss) 1.5 Mepolizumab (Nucala) 1.6 Omalizumab (Xolair) 1.7 Reslizumab (Cinqaero) 1.8 Tezepelumab (Tezspire) Q2. How many patients were treated for severe asthma, COPD, CRwNP with the following medicines in the 3 months between the start of July 2026 and the end of September 2026? 2.1 Benralizumab (Fasenra) 2.2 Depemokimab (Exdensur) 2.3 Dupilumab (Dupixent) 2.4 Mepolizumab (Nucala) 2.5 Omalizumab (Xolair) 2.6 Reslizumab (Cinqaero) 2.7 Tezepelumab (Tezspire) Q3. How many patients were treated by department in total, regardless of diagnosis, with the following medicines in the 3 months between the start of July 2026 and the end of September 2026? 3.1 Benralizumab (Fasenra) 3.2 Depemokimab (Exdensur) 3.3 Dupilumab (Dupixent) 3.4 Mepolizumab (Nucala) 3.5 Omalizumab (Xolair) 3.6 Reslizumab (Cinqaero) 3.7 Tezepelumab (Tezspire) Q4. How many patients with the following diagnoses were treated with Dupilumab in the 3 months between the start of July 2026 and the end of September 2026? Other chronic obstructive pulmonary disease Other specified chronic obstructive pulmonary disease Other specified chronic obstructive pulmonary disease Asthma-chronic obstructive pulmonary disease overlap syndrome Acute exacerbation of chronic obstructive pulmonary disease with asthma Chronic asthma with fixed airflow obstruction Chronic asthmatic bronchitis Q5. How many patients with the following diagnoses were treated with Mepolizumab in the 3 months between the start of July 2026 and the end of September 2026? Other chronic obstructive pulmonary disease Other specified chronic obstructive pulmonary disease Other specified chronic obstructive pulmonary disease Asthma-chronic obstructive pulmonary disease overlap syndrome Acute exacerbation of chronic obstructive pulmonary disease with asthma Chronic asthma with fixed airflow obstruction Chronic asthmatic bronchitis
Date of Response: 16/11/2026
View Response: 12054.pdf

Freedom of Information Request Reference: 12053
Date Received: 15/10/2026
Summary:
How many people were treated in the last 6-month period with branded or generic emtricitabine / tenofovir disoproxil (Truvada) for HIV treatment? How many people were treated in the last 6-month period with branded or generic emtricitabine / tenofovir disoproxil for pre-exposure prophylaxis (PrEP)? How many packs of branded or generic emtricitabine / tenofovir disoproxil were dispensed in latest 6-month period for HIV treatment? How many packs of branded or generic emtricitabine / tenofovir disoproxil were dispensed in latest 6-month period for pre-exposure prophylaxis (PrEP)? How many people were treated in the last 6-month period with emtricitabine / tenofovir alafenamide (Descovy) for HIV treatment? How many people were treated in the last 6-month period with emtricitabine / tenofovir alafenamide for pre-exposure prophylaxis (PrEP)? How many packs of emtricitabine / tenofovir alafenamide were dispensed in latest 6-month period for HIV treatment? How many packs of emtricitabine / tenofovir alafenamide were dispensed in latest 6-month period for pre-exposure prophylaxis (PrEP)?
Date of Response: 16/11/2026
View Response: 12053.pdf

Freedom of Information Request Reference: 12051
Date Received: 14/10/2026
Summary:
Please provide the number of reports or disclosures of domestic abuse (experienced by patients or disclosed on behalf of patients) recorded by maternity services across the health board in each of the last five years, including 26-27 year to date. For the purposes of this request, domestic abuse includes abuse by a current or former partner or other family member, including physical, sexual, emotional, psychological, financial or coercive and controlling behaviour.
Date of Response: 16/11/2026
View Response: 12051.pdf

Freedom of Information Request Reference: 12050
Date Received: 14/10/2026
Summary:
I would be grateful if you could tell me how many patients were treated in the 3 months between July and September 2026 for the list of drugs named in the questions below. Q1. How many patients were treated in total regardless of diagnosis with the following drugs between 1st July 2026 and 30th September 2026, or the latest 3-month period for which you have data? Adalimumab Etrasimod Filgotinib Golimumab Guselkumab Infliximab Mirikizumab Ozanimod Risankizumab Tofacitinib Upadacitinib Ustekinumab Vedolizumab Q2. How many patients were treated by the Gastroenterology Department with the following drugs between 1st July 2026 and 30th September 2026, or the latest 3-month period for which you have data? Adalimumab Etrasimod Filgotinib Golimumab Guselkumab Infliximab Mirikizumab Ozanimod Risankizumab Tofacitinib Upadacitinib Ustekinumab Vedolizumab Q3. How many patients with Crohn’s Disease, Ulcerative Colitis or Inflammatory Bowel Disease NOS in total regardless of department / clinic, were treated with the following drugs between 1st July 2026 and 30th September 2026, or the latest 3-month period for which you have data? Adalimumab Etrasimod Filgotinib Golimumab Guselkumab Infliximab Mirikizumab Ozanimod Risankizumab Tofacitinib Upadacitinib Ustekinumab Vedolizumab
Date of Response: 16/11/2026
View Response: 12050.pdf

Freedom of Information Request Reference: 12048
Date Received: 14/10/2026
Summary:
For each calendar year from 2021 to 2025 inclusive, please provide the following information for medicinal products purchased, supplied or dispensed by your Trust for the treatment of haemophilia A, haemophilia B or patients with inhibitors: 1. Product name, manufacturer, presentation and strength 2. Total packs and administration units purchased, supplied or dispensed 3. Total quantity in IU or mg, where recorded 4. Number of unique patients treated with each product during that year, where available
Date of Response: 13/11/2026
View Response: 12048.pdf

Freedom of Information Request Reference: 12045
Date Received: 13/10/2026
Summary:
Q1. How many patients were treated with SACT therapy only, as opposed to radiotherapy or surgery, for the following types of cancer? Please count for the 12 months between 1st October 2025 and the end of September 2026, or latest 12-months for which data are available. 1.1 Colorectal Cancer C18*, C19*, C20* 1.2 Colon Cancer C18* Q2. How many patients were treated with SACT therapy only, as opposed to radiotherapy or surgery, for the following types of cancer? Please count for the 3 months between 1st July 2026 and the end of September 2026, or latest 3-months for which data are available. 2.1 Colorectal Cancer C18*, C19*, C20* 2.2 Colon Cancer C18* Q3. How many patients with the following types of cancer were treated with surgical resection in the past 3 months from 1st July 2026 to the end of September 2026?  3.1 Colorectal Cancer C18*, C19*, C20* 3.2 Colon Cancer C18* Q4. How many patients with the following types of cancer received SACT therapy as Adjuvant treatment in the past 3 months from 1st July 2026 to the end of September 2026?  4.1 Colorectal Cancer C18*, C19*, C20* 4.2 Colon Cancer C18* Q5. How many patients with Colorectal Cancer (ICD-10 C18*, C19* & C20*) received these treatment combinations as adjuvant therapy in the past 3 months from 1st July 2026 to the end of September 2026?  5.1 FOLFOX Fluorouracil + Folinic Acid + Oxaliplatin 5.2 XELOX Capecitabine + Oxaliplatin 5.3 FOLFIRI Fluorouracil + Folinic Acid + Irinotecan 5.4 XELIRI Capecitabine + Irinotecan 5.5 Nivolumab + Ipilimumab Q6. How many patients with Colon Cancer (ICD-10 C18*) received these treatment combinations as adjuvant therapy in the past 3 months from 1st July 2026 to the end of September 2026?  6.1 FOLFOX Fluorouracil + Folinic Acid + Oxaliplatin 6.2 XELOX Capecitabine + Oxaliplatin 6.3 FOLFIRI Fluorouracil + Folinic Acid + Irinotecan 6.4 XELIRI Capecitabine + Irinotecan 6.5 Nivolumab + Ipilimumab Q7. How many patients were treated with cemiplimab (Libtayo) for the following types of cancer in the 3 months between 1st July 2026 to the end of September 2026, or latest 3-months for which data are available?  7.1 Cutaneous Squamous Cell Carcinoma 7.2 Basal Cell Carcinoma 7.3 Non-small Cell Lung Cancer 7.4 Cervical Cancer Q8. How many patients treated with cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma were treated with the following treatment intent in the 3 months between 1st July 2026 to the end of September 2026, or latest 3-months for which data are available?  8.1 Curative 8.2 Palliative Q9. How many patients received cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma as adjuvant treatment in the 3 months between 1st July 2026 to the end of September 2026, or latest 3-months for which data are available?  9.1 Adjuvant
Date of Response: 16/11/2026
View Response: 12045.pdf

Freedom of Information Request Reference: 12040
Date Received: 13/10/2026
Summary:
Please provide the following information: 1. a) The number of CT scanners that your health board possesses b) The number of CT scanners older than ten years old that your health board possesses c) The age of the oldest CT scanner still in use d) The longest number of days a CT scanner has been out of service within the last three years e) The longest wait for a repair of a CT scanner within the last three years 2. a) The number of MRI scanners that your health board possesses. b) The number of MRI scanners older than ten years old that your health board possesses. c) The age of the oldest MRI scanner still in use. d) The longest number of days an MRI scanner has been out of service within the last three years e) The longest wait for a repair of an MRI scanner within the last three years 3. a) The number of X Ray machines that your health board possesses b) The number of X Ray machines older than ten years old that your health board possesses c) The age of the oldest X Ray machine still in use d) The longest number of days an X Ray machine has been out of service within the last three years e) The longest wait for a repair of an X Ray machine within the last three years
Date of Response: 16/11/2026
View Response: 12040.pdf

Freedom of Information Request Reference: 12035
Date Received: 12/10/2026
Summary:
For each calendar year 2023, 2024, 2025, and the most recent date for which data is available in 2026: 1. The number of dental practices within the Board area that: o ceased providing NHS dental services entirely; and/or o terminated, surrendered, or handed back an NHS dental contract or equivalent arrangement. 2. The number of dental practices that reduced the level of NHS dental services they provide, including: o reducing NHS patient capacity; o reducing NHS clinical sessions; or o otherwise restricting NHS provision, where such information is held. 3. Where recorded, please provide any reasons given by practices for: o ceasing to provide NHS dental services; or o reducing NHS dental provision. 4. Please provide the number of NHS dental practices operating within the Board area at the end of each year (or at the most recent date available in 2026). 5. Please provide the number of NHS dental practices accepting new NHS patients at the end of each year (or at the most recent date available in 2026), if held. 6. Please provide the number of NHS dental practices within the Board area that closed permanently during each year.
Date of Response: 16/11/2026
View Response: 12035.pdf

Freedom of Information Request Reference: 12030
Date Received: 09/10/2026
Summary:
Please provide the following about the Board's pressure-relieving equipment and pressure ulcer prevention. 1. The Board's spend on pressure-relieving support surfaces (mattresses and mattress replacement systems, overlays, cushions, and any automated turning, lateral rotation or turn-assist devices) in each financial year, split by purchase, rental or hire, and managed service, and by manufacturer and supplier. 2. For dynamic (powered) mattresses that are rented, hired or provided under a managed service: the supplier, the contract or framework used, its start and end dates, and the number of rental days (or units) and the cost in each financial year. 3. The number of pressure-relieving mattresses the Board owned at 31 March 2026, by type (high-specification foam, hybrid, dynamic or alternating air, and lateral turning or rotation), and the date of any planned replacement or re-procurement. 4. The Board's current mattress or support surface selection policy and repositioning standard (a link or copy is enough), and whether the Board uses any automated turning, lateral rotation or turn-assist device, with the product name and number in use. 5. The number of pressure ulcers that developed in the Board's care in each financial year, by category (2, 3, 4, unstageable, suspected deep tissue injury, and medical device related). 6. The number of patient safety incidents recorded in 2025/26 where pressure-relieving equipment was unavailable or delayed and, if the Board records it, the median time from request to provision of a dynamic mattress. 7. The group that evaluates new pressure area care equipment; its meeting dates from 1 April 2026 to 31 March 2027; and the submission process and evidence required from a supplier. Please provide the information for financial years 2023/24, 2024/25 and 2025/26. Where a product was bought through NHS National Procurement or another distributor, please give the manufacturer separately from the supplier. I am content to receive a raw extract from your purchasing, catalogue or service system in any format, including a spreadsheet, without reformatting.
Date of Response: 17/11/2026
View Response: 12030.pdf

Freedom of Information Request Reference: 12028
Date Received: 07/10/2026
Summary:
Contract & supplier 1. Are you in contract for a managed print service? Is it fully outsourced? 2. Who is the incumbent supplier for each category above? 3. What is the manufacturer/brand of the devices (if different to Q2)? 4. What is the contract start date and end date for each, and what extension options remain? 5. How was it procured — direct award or mini-competition? If via a framework, which one (e.g. CCS RM6174, KCS, ESPO, YPO, NHS Supply Chain, NOE CPC, LPP)? Scale & spend 6. How many MFDs and how many printers do you have? 7. What is the annual spend on the managed print service (lease, cost-per-click, consumables, service)? 8. What are your annual print volumes (mono and colour)? 9. How many sites/locations does the contract cover? Software & capability 10. What print-management software do you use (e.g. PaperCut, Equitrac, uniFLOW, YSoft SafeQ)? 11. Do you have secure/follow-me print and mobile print capability? 12. What device/fleet remote-monitoring software do you use? Renewal & ownership 13. Any planned procurement to replace or re-tender print/MFDs in the next 24 months? If so, when and via which framework? 14. What is the job title/role of the person responsible for the print estate, and the generic team contact for print procurement?
Date of Response: 18/11/2026
View Response: 12028.pdf

Freedom of Information Request Reference: 12022
Date Received: 08/10/2026
Summary:
I am looking for information about serious adverse event reviews that have been carried out by your health board in the last three and a half years. Can you provide me with the following information for the time periods: • 2023 • 2024 • 2025 • 1 January 2026 to the date of this request For each year, please provide: • The total number of Serious Adverse Event Reviews (SAERs) undertaken by the Health Board. • The total number of Serious Adverse Event Reviews (SAERs) undertaken by the Health Board which were carried out following a death. • The total number of reviews in Q1 and Q2 that had recommendations in each of the years specified. I am also looking to quantify the number of suicide reviews, which are not covered by the figures on SAERs above For each year, please provide: • The total number of suicide reviews that are not covered by the previous question undertaken by the Health Board. • The total number of suicide reviews that are not covered by the previous question undertaken by the Health Board which were carried out following a death. • The total number of reviews in Q1 and Q2 that had recommendations in each of the years specified.
Date of Response: 17/11/2026
View Response: 12022.pdf

Freedom of Information Request Reference: 11878
Date Received: 03/09/2026
Summary:
1. Services Provided A comprehensive list of all women’s healthcare services currently delivered within NHS Lothian, including: • Gynaecology • Menopause services • Fertility and reproductive health • Pelvic pain, endometriosis, adenomyosis and PMDD pathways • Maternity care • Women’s mental health services • Specialist clinics (e.g., recurrent miscarriage, complex hormonal conditions) For each service, please outline scope, eligibility criteria, and geographical availability. 2. Costs, Funding & Residuals For each service listed above, please provide: • Annual cost of delivering the service • Per patient cost where available • National and regional funding allocations • Any additional investment made under the Women’s Health Plan • A breakdown of money spent versus money allocated • Details of any residual or unspent funds, including: o The amount of residual funding o Where these residual funds were redirected o The rationale for redirecting or retaining residual funds o Any governance decisions or financial controls applied 3. Service Usage Data showing how women are currently using these services, including: • Annual patient numbers • Referral volumes • Waiting list sizes • Average waiting times • Demographic breakdowns where available 4. Goals and Targets Information on national and regional goals relating to women’s healthcare, including: • Strategic priorities • Targets for waiting times, outcomes, and service expansion • Commitments under the Women’s Health Plan and subsequent updates 5. Performance and Outcomes Performance data for each service area, including: • Key performance indicators • Outcome measures • Patient satisfaction data • Published audits, evaluations, or improvement plans 6. Hospital Admissions • Within the Health-board where patient is on waiting list to be seen • Outcome measures • Patient satisfaction data • Published audits, evaluations, or improvement plans
Date of Response: 17/11/2026
View Response: 11878.pdf

Freedom of Information Request Reference: 11972
Date Received: 28/09/2026
Summary:
The minutes of the the meeting on 5th May seem to have been omitted. In addition I would like the documents referred to in the minutes : Minutes of 3 Feb 2026 Item 6.1 and 7.1 refer to a paper on proposed arramgenebts for transition of existing structures, I assume item 6. 1nad 7.1 refer to the same document item 9.2 9.2. A “Handbook” had been prepared which included the key components of the East Region approach and its intended outputs. 10.1. The Group received a paper highlighting the need to establish a clear baseline on the East Region’s built infrastructure assets, capacity and requirements. Minutes of 31 Marrch 2026 3. Confirmation of Plan Submission 3.1 Members noted that the plan had been submitted earlier today,......... id like a copy of the submitted plan . meeting of 5 May seem to be omitted Meeting of 2 June 10. Additional item – Proposed New Model of Unscheduled Care 10.1 In an amendment to the circulated agenda, a presentation was delivered outlining a proposed redesign of Unscheduled Care, foc
Date of Response: 16/11/2026
View Response: 11972.pdf

Freedom of Information Request Reference: 12033
Date Received: 12/10/2026
Summary:
Please provide the following data broken down by financial year for each of the last three available cycles (e.g., 2023/24, 2024/25, and 2025/26): 1. SOU Discharge to Community Death (Within 48 Hours) The total number of adult patients discharged from the RIE Surgical Observation Unit (SOU) to their home, a relative's home, or a non-hospital care setting who died within 72 hours of their recorded discharge time, as identified via SMR01/National Records of Scotland (NRS) death record linkage. 2. SOU Discharge to Emergency Readmission and Death (Within 48 Hours) The total number of adult patients discharged from the RIE Surgical Observation Unit (SOU) who were subsequently readmitted to the RIE Emergency Department (ED) as an emergency within 72 hours of that discharge, and who subsequently died within 72 hours of their original SOU discharge. 3. Internal Review and Audit Counts Of the cases identified in Questions 1 and 2, how many were formally escalated to: • a) A local Morbidity and Mortality (M&M) review? • b) A formal Significant Adverse Event Review (SAER) or Adverse Event Review (AER)?
Date of Response: 12/11/2026
View Response: 12033.pdf

Freedom of Information Request Reference: 12178
Date Received: 10/11/2026
Summary:
Request in relation to information governance.
Date of Response: 10/11/2026
View Response: 12178.pdf

Freedom of Information Request Reference: 12063
Date Received: 16/10/2026
Summary:
1. A copy of your current clinical guideline or protocol for the management of nausea and vomiting in pregnancy and hyperemesis gravidarum, including its publication and review dates. If it is published online, a link is sufficient. If you do not have one, please say so. 2. Whether you offer ambulatory (day-case) treatment for hyperemesis gravidarum, such as IV fluids without overnight admission. A yes or no answer is sufficient.
Date of Response: 10/11/2026
View Response: 12063.pdf

Freedom of Information Request Reference: 12059
Date Received: 13/10/2026
Summary:
I’m trying to find out what facilities there are at the Royal Infirmary of Edinburgh for bed-bound patients. Are they able to watch television on an individual basis? Is there a radio by every bed? What is done to make their lives more bearable during the day when they don’t have visitors? When I visited a friend, I noticed a box for dispensing pay-to-view cards. Is this the route to watching TV if you are unable to walk to a common room?
Date of Response: 10/11/2026
View Response: 12059.pdf

Freedom of Information Request Reference: 12049
Date Received: 14/10/2026
Summary:
I would like to make a freedom of information request about prostate-specific antigen (PSA) blood tests carried out within NHS Lothian Board. Please provide your response in accordance with the Freedom of Information (Scotland) Act 2002 (FOISA). 1. Between 2021 and 2025, by calendar year, how many PSA tests were performed in primary care? 2. Following on from Q1, how many of those PSA tests produced a result above the applicable referral threshold? 3. Of those identified in Q2, how many were referred to Urology? 4. Of those identified in Q2, how many received a prostate MRI? 5. Of those identified in Q2, how many underwent a prostate biopsy? 6. Of those identified in Q2, how many were subsequently diagnosed with prostate cancer (ICD-10 C61)? 7. For those subsequently diagnosed with prostate cancer (ICD-10 C61), please provide the stage at diagnosis, broken down by year between 2021 and 2025. 8. Please provide any local guidelines, policies or clinical pathways covering the process from PSA testing to treatment for prostate cancer (ICD-10 C61).
Date of Response: 10/11/2026
View Response: 12049.pdf

Freedom of Information Request Reference: 12047
Date Received: 14/10/2026
Summary:
Questionnaire in relation to HIV service.
Date of Response: 10/11/2026
View Response: 12047.pdf

Freedom of Information Request Reference: 12046
Date Received: 13/10/2026
Summary:
The request covers all NHS Lothian hospital sites with operating theatres, including the Princess Alexandra Eye Pavilion, St John’s Hospital, Western General Hospital, Royal Infirmary of Edinburgh and Royal Hospital for Children and Young People. For the period 1 April 2023 to 30 September 2026, I am seeking existing records of theatre downtime, delayed or cancelled activity, financial impact and contingency arrangements. The purpose is to understand the implications for theatre resilience and the costs associated with disruption and recovering cancelled activity. I appreciate that some information may not be separately recorded. The attached letter allows for existing reports and extracts, without requiring a new financial model or patient-level information. If the scope requires refinement, please advise what can be supplied within the applicable limits, prioritising AGSS incidents and their recorded financial consequences.
Date of Response: 10/11/2026
View Response: 12046.pdf

Freedom of Information Request Reference: 12044
Date Received: 13/10/2026
Summary:
For each of the services listed below, please provide: a. whether your organisation currently commissions or directly provides the service outside a hospital setting, yes or no; b. the name of each provider organisation or practice delivering it, whether contracted or provided directly; c. a copy of the current service specification, or a web link if it is already published. Vasectomy. Carpal tunnel decompression. Any other surgical procedure provided in a community or primary care setting, for example trigger finger release, ganglion excision, ingrowing toenail surgery or other minor surgery delivered under a separate arrangement.
Date of Response: 09/11/2026
View Response: 12044.pdf

Freedom of Information Request Reference: 12038
Date Received: 12/10/2026
Summary:
How many new patients were treated by the Trust's Gastroenterology Department in the latest 3 month period of May, June and July (or the latest 3 months available) with the treatments I have provided below? Please can you define a "new patient" as a patient who has received any of the treatments listed below for the first time. Adalimumab [Humira] Adalimumab [All Biosimilar] Etrasimod Filgotinib Golimumab [Simponi] Golimumab [All Biosimilar] Guselkumab Infliximab [Remicade] Infliximab [All Biosimilar] Mirikizumab Ozanimod Risankizumab Tofacitinib Upadacitinib Ustekinumab [Stelara] Ustekinumab [All Biosimilar] Vedolizumab
Date of Response: 10/11/2026
View Response: 12038.pdf

Freedom of Information Request Reference: 12034
Date Received: 12/10/2026
Summary:
If a patient attends your Trust's ED, UTC or MIU with a suspected scaphoid fracture, but normal initial X-rays, I would like to know how these patients are managed. Specifically: What is your Trust/typical follow up pathway, including expected timescales, for these patients? (e.g. referral to fracture clinic and review at 2 weeks, or discharge with advice and to return if any concerns) What imaging follow up is conducted on these patients and at what time interval typically (e.g. repeat X-ray then MRI, CT, etc.) Please supply a copy of your local clinical guidelines/pathways and patient advice leaflet you use
Date of Response: 10/11/2026
View Response: 12034.pdf

Freedom of Information Request Reference: 12032
Date Received: 12/10/2026
Summary:
1. Does your health board operate a workplace drug and alcohol testing policy for staff (including staff working in substance misuse and addiction services)? If so, please provide a copy of the current policy, or confirm the date it was last reviewed. 2. Does the policy include the following safeguards: (a) Engagement of an independent Medical Review Officer (MRO) or equivalent qualified professional to review positive drug test results before any disciplinary action is taken; (b) Obtaining an independent toxicological opinion when a positive result may be attributable to legal substances (such as over-the-counter CBD products, prescription medication, or dietary sources); (c) Offering confirmatory re-testing or independent analysis following a disputed positive result; (d) Referral to Occupational Health before disciplinary proceedings are initiated on the basis of a drug test result; (e) Maintenance of a written drug and alcohol testing policy that meets the standards recommended by the ACAS guidance on managing drug and alcohol misuse at work? 3. What type of drug screening devices or methods are used for initial testing (e.g. oral fluid point-of-care immunoassay, urine immunoassay, laboratory analysis)? 4. Are all positive screening results confirmed by a second, independent analytical method (specifically GC-MS or LC-MS/MS) before any disciplinary, welfare or employment decision is made? 5. Is your health board aware that peer-reviewed literature confirms that lawful, everyday substances can produce false positive results on immunoassay-based screening devices? Documented sources of cross-reactivity include poppy seeds, over-the-counter CBD products, prescribed medications (including codeine, tramadol, gabapentin and certain antidepressants), tonic water, bananas, passive or environmental exposure to cannabis smoke, and certain antihistamines, among others. 6. Has your health board received any complaints, grievances or representations from staff who attributed a positive drug test result to any lawful source in the last five years? If so, how many and what was the outcome? 7. What guidance, if any, has been issued to staff involved in drug testing about the possibility of false positives from lawful substances, and the appropriate steps to take before acting on a screening result? 8. If your health board does not drug test staff: what procedure applies if a member of staff is reasonably suspected of being under the influence of drugs or alcohol at work (for example removal from duty, Occupational Health referral or the disciplinary process), and where is this written down?
Date of Response: 10/11/2026
View Response: 12032.pdf

Freedom of Information Request Reference: 12031
Date Received: 12/10/2026
Summary:
I wonder if you could be so kind as to let me know how many patients at the Royal Edinburgh hospital for mental health have died in each year from 2019 till now. Ie the yearly figure of patients that have been on SSRI'S as an outpatient dying after being treated by the royal Edinburgh hospital for mental health. Can u please have the annual figure (as far back as you can go please) of deaths from outpatients seeking help from the royal Edinburgh hospital for mental health when they were suffering psychosis or SERITONAN SYNDROME?
Date of Response: 10/11/2026
View Response: 12031.pdf

Freedom of Information Request Reference: 12026
Date Received: 09/10/2026
Summary:
I would like the internal review to consider whether the following information could be identified through existing NHS Lothian records: 1. The number of patients referred or transferred to the Plastic Surgery service at St John’s Hospital, Livingston, following complications arising from privately funded cosmetic or plastic surgery. 2. Whether existing Plastic Surgery referral records, admission records, theatre activity records, service audits or other routinely held information could identify patients who required emergency NHS treatment following privately funded procedures. 3. Whether the originating private hospital or provider is recorded within referral or transfer information, particularly where patients were referred directly to a specialist surgical team rather than presenting through a standard Emergency Department pathway. 4. Whether existing records identify patients who were discharged or referred back to their original private hospital or provider for ongoing postoperative care following NHS treatment. 5. Whether any existing reports, audits or statistical information identify referrals or admissions originating from St Ellen’s Hospital/Cosmedicare specifically. 6. Whether a request restricted to St John’s Hospital, the Plastic Surgery service or a shorter reporting period could be answered within the applicable cost limit.
Date of Response: 06/11/2026
View Response: 12026.pdf

Freedom of Information Request Reference: 12025
Date Received: 08/10/2026
Summary:
A. How many total patients and new patients have been treated with the following drugs in the past 4 months (June to September 2026): Atogepant Erenumab Eptinezumab Fremanezumab Galcanezumab Rimegepant Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY B. How many patients have you treated in the last 4 months (June to September 2026) for ACUTE migraine with: • Rimegepant (Vydura) • Atogepant (Aquipta)
Date of Response: 10/11/2026
View Response: 12025.pdf

Freedom of Information Request Reference: 12021
Date Received: 07/10/2026
Summary:
I am requesting access to the following information from your Health Board for each calendar year from 2018 to 2026 (most recent): 1. The total number of referrals for hernia repair broken down by different types of hernias. a. The median waits for hernia repair broken down by different types of hernias. b. Median wait time variation for more simple hernia repair procedures (e.g., Inguinal/Parastomal) versus more complex hernia procedures, and type of clinical staff completing each hernia repair procedure. 2. The 5 longest completed waits for hernia repair broken down by different types of hernias and type of clinical staff completing each hernia repair procedure. 3. The 5 longest ongoing waits for hernia repair broken down by different types of hernias. 4. Please provide the budget allocation and total expenditure by your board utilized to help eliminate Hernia repair waiting times for each calendar year from 2018 to 2026 (most recent).
Date of Response: 10/11/2026
View Response: 12021.pdf

Freedom of Information Request Reference: 12018
Date Received: 07/10/2026
Summary:
1. As at 30 September 2026, what is the number of medical consultant posts (all consultants regardless of specialty including NHS and honorary) in your board by WTE for the following (please note that all posts should be counted under ONE category only): i. posts occupied by a permanent consultant ii. newly-created posts which have not yet been advertised iii. vacant posts according to the ISD definition (“a post which has been cleared for advert after being through the redeployment process (internal or external advert) and remains a vacancy until an individual starts in the post”) iv. vacant posts which are awaiting approval for recruitment v. posts which although currently unfilled are not under active recruitment, e.g. where a previous recruitment exercise has been unsuccessful vi. all posts occupied by a locum consultant (including consultants re-engaged as locums who previously held a permanent post and those locum consultants employed via an agency) vii. posts that have been recruited to but applicant not yet in post (e.g. deferred start due to pending CCT) viii. the number of consultants that are on fixed term contracts ix. other (please be specific) 2. As of 30 September 2026, how many of the posts listed under iii-viii above have not been occupied by a permanent substantive post holder since 31 March 2026? As of 30 September 2026, what is the number of SAS (Specialty doctors, Specialists, Associate Specialists, or staff grades) doctors in your board by WTE for the following (please note that all posts should be counted under ONE category only): i. posts occupied by a permanent SAS doctor ii. newly created posts which have not yet been advertised (including new Specialist posts) iii. vacant posts according to the definition “a post which has been cleared for advert after being through the redeployment process (internal or external advert) and remains a vacancy until an individual starts in the post” iv. vacant posts which are awaiting approval for recruitment v. posts which although currently unfilled are not under active recruitment, e.g. where a previous recruitment exercise has been unsuccessful vi. all posts occupied by a locum SAS doctor (including those locum specialty doctors employed via an agency) vii. posts that have been recruited to but applicant not yet in post viii. The number of SAS doctors on fixed term contracts ix. other (please be specific) 3. As of 30 September 2026, how many of the posts listed under iii – viii above have not been occupied by a permanent substantive post holder since 31 March 2026?
Date of Response: 10/11/2026
View Response: 12018.pdf

Freedom of Information Request Reference: 12017
Date Received: 07/10/2026
Summary:
Please see specific questions below and if the information could please be presented in Excel format. 1. Are there operating table-mounted surgical retractor systems currently in use within the trust/HB? 2. How many complete retractor systems are in use? 3. Are these retractor systems manufactured by: • Thompson Retractor • Omni-Tract® (Integra LifeSciences) • Other manufacturer 4. Location within trust (hospital site) 5. Surgical specialities sets are used in 6. Age of each set-in situ (date of manufacture or date of installation) 7. Associated planned replacement programmes or supplier contracts in place
Date of Response: 10/11/2026
View Response: 12017.pdf

Freedom of Information Request Reference: 12012
Date Received: 06/10/2026
Summary:
1. Surgical robots: How many robot-assisted surgical systems (for example, da Vinci, Versius, Hugo, Mako, ROSA) does the health board currently have in use? For each one, please give the manufacturer and model, the year it came into use, and the hospital site where it is based. 2. Number of operations: How many robot-assisted surgical procedures did the health board carry out in each financial year from 2019/20 to 2025/26? 3. By specialty: For each of those years, please break the total down by surgical specialty (for example: urology, colorectal or general surgery, gynaecology, ear nose and throat, thoracic, orthopaedics, other). 4. Costs: What was the purchase or lease cost of each robot, and what is the current annual maintenance or service contract cost?
Date of Response: 10/11/2026
View Response: 12012.pdf

Freedom of Information Request Reference: 12007
Date Received: 05/10/2026
Summary:
1. What is your Trust’s capital and revenue IT spend for the following financial year? FY 2025/2026 (£): 2. Please break this figure down into the following categories, providing the capital and revenue cost for each, for the above requested financial year: a. IT staff cost b. Software c. Services d. Hardware e. Communication equipment f. Other IT spend
Date of Response: 10/11/2026
View Response: 12007.pdf

Freedom of Information Request Reference: 11999
Date Received: 05/10/2026
Summary:
Please could you provide the following information about the portable ambulatory infusion pumps your Trust uses for patient-controlled analgesia (PCA), epidural analgesia, and regional anaesthesia. Figures as at the date of your reply are fine. 1. The manufacturer, model name, and number of each pump model currently in service, with a breakdown by hospital site where this is recorded. 2. The clinical use of each model (PCA, epidural, regional anaesthesia or more than one), if recorded. 3. The year each model was purchased or first put into use. 4. How each model was procured (framework agreement, tender, direct award or managed service), and the framework name if one was used. 5. The contract starts and end dates, where applicable. 6. The department or role responsible for procurement and for ongoing management and maintenance of these pumps.
Date of Response: 10/11/2026
View Response: 11999.pdf

Freedom of Information Request Reference: 11983
Date Received: 30/09/2026
Summary:
I am writing to request information under the Freedom of Information (Scotland) Act 2002 regarding the key clinical, diagnostic, infrastructure, corporate and patient-facing digital systems currently used by your NHS Board. Please complete the attached spreadsheet, with the following information for each system area listed, where applicable: • Current supplier • Product or system name • Contract start date • Contract end date • Any available extension options • Current annual contract value • Current total contract value, including any extension options
Date of Response: 06/11/2026
View Response: 11983.pdf

Freedom of Information Request Reference: 11948
Date Received: 17/09/2026
Summary:
A list of current contracts for ICT services, network and connectivity, telephony and unified communications, data centre or hosting, enterprise software (finance, HR, housing, social care or similar) and programme or project management services. For each contract please give the supplier name, a short description, the start date, the end date, any extension options, the annual or total value and the job title of the contract owner. If this information is published in the organisation's contracts register under the Local Government Transparency Code, a link to the current register is a complete answer.
Date of Response: 06/11/2026
View Response: 11948.pdf

Freedom of Information Request Reference: 11929
Date Received: 17/09/2026
Summary:
1. Expenditure over the last five financial years Please provide the total amount actually spent by NHS Lothian in each of the following financial years: • 2021/22 • 2022/23 • 2023/24 • 2024/25 • 2025/26 on LGBTQ+ / LGBT+ / LGBT / LGBTQIA+ / LGBTQIA / LGBTI+ / LGBTI or equivalent initiatives, campaigns, promotional activity or materials. Please provide the figures separately for each financial year. 2. Promotional materials For each of the five financial years above, please provide expenditure specifically relating to promotional or branded materials connected with the above initiatives. Please include, where applicable: • pins; • badges; • lanyards; • stickers; • wristbands; • flags; • posters; • banners; • leaflets; • brochures; • printed literature; • clothing; • merchandise; • promotional displays; • digital promotional materials; • other promotional items. Please provide the total expenditure for each financial year and, where this information is readily available, a breakdown by type of item. 3. NHS pins and similar items Please specifically provide details of any NHS Lothian expenditure on LGBTQ+ themed or Pride-related pins, badges or similar wearable promotional items during the last five financial years. For each financial year, please provide: a) total amount spent; b) number of items purchased; c) type of item; d) unit cost, where available; e) supplier; f) date of purchase; g) purpose/use of the items, where recorded. If the items were supplied free of charge or at no cost to NHS Lothian, please state this. 4. Other LGBTQ+ promotional expenditure Please provide details of expenditure on any other LGBTQ+ promotional or awareness materials or activities during the same period. Where readily available, please identify: a) the item or activity; b) amount spent; c) date of expenditure; d) supplier or organisation paid; e) relevant NHS Lothian department or service; f) stated purpose of the expenditure. 5. Budget allocations For each of the five financial years 2021/22 to 2025/26, please provide the amount of budget formally allocated, ring-fenced, earmarked or otherwise set aside by NHS Lothian specifically for: a) LGBTQ+ / LGBT+ / LGBT / LGBTQIA+ / LGBTI+ or equivalent initiatives; b) LGBTQ+ promotional or awareness materials; c) LGBTQ+ campaigns, events or promotional activity. Please distinguish between: • budget allocated; • actual expenditure; • unspent budget, where recorded. 6. Next financial year Please provide the amount of budget currently allocated, approved, earmarked or proposed for the next financial year, 2026/27, specifically for: a) LGBTQ+ / LGBT+ / LGBT / LGBTQIA+ / LGBTI+ or equivalent initiatives; b) LGBTQ+ promotional or awareness materials; c) LGBTQ+ campaigns, events or promotional activity. Please clearly identify whether each figure is: • formally approved; • allocated but not yet spent; • proposed; • provisional; • or otherwise planned. 7. Staff and external organisations Please provide details of any expenditure during the five-year period on external organisations, consultants, charities, equality organisations or other third parties specifically engaged to provide LGBTQ+ awareness, training, promotional or related services. For each financial year, please provide: a) organisation/provider; b) amount paid; c) service or purpose; d) date/period of engagement. Please exclude ordinary NHS staff salaries unless an employee was specifically employed in a role whose primary purpose was an LGBTQ+-specific programme or initiative. If such staff costs are included, please identify them separately. 8. Events and campaigns Please provide the total amount spent by NHS Lothian in each of the five financial years on LGBTQ+ / Pride-related events, campaigns or promotional activities. Where available, please identify: • event/campaign name; • date; • expenditure; • supplier/provider; • purpose. 9. Funding source and budget holder For the expenditure identified above, please provide the relevant NHS Lothian department, directorate, programme, cost centre or budget heading from which the expenditure was funded, where this information is readily available. Please also state whether the expenditure was funded from: • NHS Lothian’s general operating budget; • an equality/diversity budget; • a staff engagement/wellbeing budget; • a communications/marketing budget; • another specific budget; • external funding. 10. Terminology/search terms When searching for the requested information, please include records using the following terms and reasonable variations thereof: • LGBTQ • LGBTQ+ • LGBTQIA • LGBTQIA+ • LGBT • LGBT+ • LGBTI • LGBTI+ • LGBTQQIA+ • Lesbian, Gay, Bisexual and Transgender • Lesbian, Gay, Bisexual, Transgender and Queer • Pride • Pride Month • LGBTQ+ equality • LGBT equality • LGBTQ+ awareness • LGBT awareness • LGBTQ+ inclusion • LGBT inclusion Please also include reasonable variations in spelling, capitalisation and punctuation. 11. Documents supporting the expenditure Please provide copies of any relevant budget papers, procurement records, invoices, purchase orders, expenditure reports or other documents which identify expenditure on LGBTQ+ promotional materials where these can be disclosed without disproportionate effort. If providing individual invoices or purchase orders would exceed the applicable cost limit, please instead provide the aggregated expenditure figures and supplier information. 12. Information not separately recorded If NHS Lothian does not maintain a specific budget or cost code for LGBTQ+ expenditure, please state this explicitly. In that circumstance, please provide any existing expenditure or budget information which can be identified using the terminology and categories above. If expenditure is incorporated within a broader equality, diversity, inclusion, communications, staff wellbeing or similar budget and cannot be separately identified, please state this and provide the name of the relevant budget/category. 13. Cost limit If any part of this request is considered too broad or would exceed the applicable cost limit, please contact me before refusing the request and identify which elements can be answered within the cost limit.
Date of Response: 10/11/2026
View Response: 11929.pdf

Freedom of Information Request Reference: 11875
Date Received: 01/09/2026
Summary:
1 - I would like to know how many women in Lothian are currently on waiting lists for this operation and also have stage 4 endometriosis. 2 - I would like to know how wait times in Lothian are comparable to other Scottish health boards.
Date of Response: 10/11/2026
View Response: 11875.pdf

Freedom of Information Request Reference: 12039
Date Received: 12/10/2026
Summary:
1. I would be grateful if you could send the most recent planning document(s) for the diagnosis and treatment of Alzheimer’s Disease, whether these are from the Health Board, Integrated Care Board (ICB), or the region. I am particularly interested in planning documents that cover lumbar punctures (CSF) and Blood Biomarker testing. 2. To what extent are there plans for service improvement of diagnosing Alzheimer’s Disease? Implementation of plans has started A plan exists and implementation has not started A plan is being developed There is no plan Other – please state 3. Are the plans for service improvement of diagnosing Alzheimer’s Disease related to: Cognitive assessment services Biomarker services None / neither 4. Which of the following services does the Health Board have in place in preparation for increased service delivery for Alzheimer’s Disease? Budget People Training Clinic space / capacity Governance arrangements 5. How many lumbar puncture procedures to test for Alzheimer’s Disease were performed in the last three-month period for which data are available? 6. Please provide the number of BBM tests for Alzheimer’s Disease conducted over the last three-months, regardless of whether they were carried out within your organisation or sent to an external pathology laboratory. 7. Which of the following biomarker tests were used to detect Alzheimer’s Disease? pTau181 immunoassay tests pTau217 immunoassay tests 8. Please provide a list of the full names of other Trusts or other organisations, to which the Health Board refers samples for pTau181 and pTau217 immunoassay testing for Alzheimer’s Disease? 9. How many pTau181 immunoassay tests were conducted to test for Alzheimer's Disease in the last three-months? 10. Is pTau181 testing for Alzheimer’s Disease linked to, or conducted in conjunction with, clinical trials? 11. How many pTau181 immunoassay tests were conducted for Alzheimer's Disease as part of a clinical trial? 12. How many pTau217 immunoassay tests were conducted to test for Alzheimer's Disease in the last three-months? 13. Is pTau217 testing for Alzheimer’s Disease linked to, or conducted in conjunction with, clinical trials? 14. How many pTau217 immunoassay tests were conducted for Alzheimer's Disease as part of a clinical trial?
Date of Response: 04/11/2026
View Response: 12039.pdf

Freedom of Information Request Reference: 12036
Date Received: 12/10/2026
Summary:
Please confirm if you operate a vendor management system for agency staff such as an MSP/neutral vendor/master vendor etc. If so, please can you name the below: -Company name -Contract start and end date -Framework utilised -Healthcare specialty used for, EG Doctors/Nursing/AHP/HSS/NMNC -Do you utilise a direct engagement model and the name of the model, e.g. TempRe/own DE model etc Please confirm if you operate a vendor management system for bank staff. If so, please can you name the below: -Company name -Contract start and end date -Framework utilised -Healthcare specialty used for, EG Doctors/Nursing/AHP/HSS/NMNC
Date of Response: 04/11/2026
View Response: 12036.pdf

Freedom of Information Request Reference: 12029
Date Received: 09/10/2026
Summary:
Could you please send me the most recent “matched job report” for band 7 Clinical Lead within Theatres at Royal infirmary of Edinburgh. I have requested both of these so I can see how job evaluation points and levels were rewarded. For this request could you please also tell me the date this report was last evaluated?
Date of Response: 02/11/2026
View Response: 12029.pdf

Freedom of Information Request Reference: 12027
Date Received: 09/10/2026
Summary:
Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage): •Avelumab + Axitinib •Axitinib •Cabozantinib •Everolimus •Lenvatinib + Everolimus •Lenvatinib + Pembrolizumab •Nivolumab monotherapy •Nivolumab + Cabozantinib •Nivolumab + Ipilimumab •Pazopanib •Pembrolizumab monotherapy •Pembrolizumab + Axitinib •Radiotherapy only •Sunitinib •Temsirolimus •Tivozanib •Other active systemic anti-cancer therapy •Palliative care only •Pembrolizumab (solution for subcutaneous injection) Q2. In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments: •Avelumab + Axitinib (Bavencio + Inlyta) •Cabozantinib (Cometriq) •Nivolumab (Opdivo) •Nivolumab + Cabozantinib (Opdivo + Cometriq) •Nivolumab + Ipilimumab (Opdivo + Yervoy) •Lenvatinib + Pembrolizumab (Kisplyx + Keytruda) •Pembrolizumab + Axitinib Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma? •Nivolumab (monotherapy) •Nivolumab + Ipilimumab •Nivolumab + Cabozantinib •Avelumab + Axitinib •Lenvatinib + Everolimus •Lenvatinib + Pembrolizumab (Kisplyx + Keytruda) •Cabozantinib (Cometriq) •Pembrolizumab + Axitinib *Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen. Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)? Q5. Does your trust participate in any clinical trials for the treatment of renal cell carcinoma? If so please provide the name of each trial and number of patients that are taking part?
Date of Response: 05/11/2026
View Response: 12027.pdf

Freedom of Information Request Reference: 12024
Date Received: 08/10/2026
Summary:
1. Is the Health Board using any implanted cardiac device / pacemaker electronic database solution? 2. If so, what is the name of the solution? 3. When is the contract due for renewal?
Date of Response: 05/11/2026
View Response: 12024.pdf

Freedom of Information Request Reference: 12023
Date Received: 08/10/2026
Summary:
1.  Do you have a Valproate Safety Implementation Group (VSIG), or an equivalent group responsible for implementing the Alert? If the group has a different title, please state it. 2.  Was the group in place before the Alert was issued, or was it established in response to the Alert? If the latter, please state the date of its first meeting. 3.  What is the job title of the chair of the VSIG, and which organisation employs them? (I do not require the individual’s name.); and which organisations, services and professional groups are represented on the VSIG? If the group has terms of reference, please provide a copy (the names of individual members may be redacted). 4.  Do you have an action or improvement plan (however titled) in response to the Alert? Please provide a copy of the most recent version held, including any recorded assessment of progress against it. 5.  Did you commission or undertake any assessment of the number and needs of patients in your area affected by the new measures (for example, a baseline audit, health needs assessment or equality impact assessment, and how many have intellectual disability and whether these are in care)? If so, please provide a copy of, or link to, the resulting document or documents. 6. If you hold this information, how many patients in your area were prescribed valproate (a) in the twelve months to 30 November 2023 and (b) in the most recent twelve-month period for which you hold figures, broken down by biological sex? If you hold a figure for how many of these patients were recorded on a learning disability register, please provide it. I recognise that you may hold prescribing data only in aggregated form (for example, as items dispensed rather than patients treated) or without these breakdowns; if so, please provide what you do hold and indicate its source. 7.  Please provide a copy of, or link to, your current local guidance, protocols or shared-care arrangements for the prescribing of valproate that reflect the regulatory measures introduced in January 2024. 8.  Do you have specific guidance for biologically female patients of childbearing potential who are prescribed valproate and who decline to participate in the Pregnancy Prevention Programme (PPP)? Please provide a copy or link to the guidance. 9.  Do you have specific guidance for patients with a learning disability (intellectual disability) who are prescribed valproate, including the assessment of their capacity to understand the teratogenic risk of valproate, to participate in the PPP and to complete the Annual Risk Acknowledgement Form (ARAF)? Please provide a copy or link to the guidance. 10. Do you hold any policy or guidance concerning patients who were previously prescribed valproate and no longer are (for example, on follow-up after discontinuation or switching, or on the identification and support of children exposed to valproate in utero)? If so, please provide a copy or link. 11. Do you hold any policy or guidance specific to the prescribing of valproate to biologically male patients, including the requirement for two specialists to approve initiation in new patients under 55 and the MHRA’s advice on paternal exposure? If so, please provide a copy or link.
Date of Response: 05/11/2026
View Response: 12023.pdf

Freedom of Information Request Reference: 12020
Date Received: 07/10/2026
Summary:
I am requesting access to the following information regarding wait times from your Health Board for the specific dates of a) December 25th , 2025 (or the closest possible date before Dec. 25), b) January 1st , 2026 (or the closest possible date before Jan. 1) and c) October 7th, 2026 (or the closest possible date before Oct. 7): 1. The median wait time for the following during the requested time frame: 1. Knee Replacement Surgery 2. Hip Replacement Surgery 3. Cataract Surgery 4. Spinal Surgery 5. Hysterectomy Surgery 6. Gallbladder Removal Surgery 7. TURP (transurethral resection of the prostate) 2. Please provide the budget allocation and total expenditure by your board utilized to help eliminate the following during the requested time frame: 1. Knee Replacement Surgery 2. Hip Replacement Surgery 3. Cataract Surgery 4. Spinal Surgery 5. Hysterectomy Surgery 6. Gallbladder Removal Surgery 7. TURP (transurethral resection of the prostate) 3. Please provide the total number of individuals on waiting lists during the requested time frame for the following: 1. Knee Replacement Surgery 2. Hip Replacement Surgery 3. Cataract Surgery 4. Spinal Surgery 5. Hysterectomy Surgery 6. Gallbladder Removal Surgery 7. TURP (transurethral resection of the prostate)
Date of Response: 03/11/2026
View Response: 12020.pdf

Freedom of Information Request Reference: 12016
Date Received: 07/10/2026
Summary:
How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: •ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) •Amivantamab Monotherapy •Atezolizumab monotherapy (any formulation) OR Atezolizumab monotherapy (infusion only) •Atezolizumab (any formulation) + Bevacizumab + Carboplatin + Paclitaxel •Atezolizumab monotherapy (subcutaneous injection only) •Dabrafenib + Trametinib •Docetaxel monotherapy or in combination with Carboplatin/Cisplatin •Durvalumab •Gemcitabine •Nintedanib + Docetaxel •Nivolumab •Osimertinib •Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) •Paclitaxel •Pembrolizumab Monotherapy •Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) •Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) •Pemetrexed + Platinum (Carboplatin/Cisplatin) •RET Inhibitors (Pralsetinib, Selpercatinib) •Sotorasib •Tepotinib •Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin •Other active systemic anti-cancer therapy •Palliative care only •Amivantamab with carboplatin and pemetrexed •Cemiplimab with platinum-based chemotherapy •Adagrasib •Datopotamab deruxtecan •Amivantamab with lazertinib •Pembrolizumab subcutaneous injection
Date of Response: 03/11/2026
View Response: 12016.pdf

Freedom of Information Request Reference: 12014
Date Received: 07/10/2026
Summary:
From 1 September 2024 to 30 September 2026, 1. Diary/schedule for Professor Caroline Hiscox for any meetings with the First Minister and/or the Cabinet Secretary for Health. 2. Any briefing headers or short descriptions accompanying the diary entry (not the full briefing unless easily retrievable). 3. If any diary entry was cancelled, rescheduled, or moved, please confirm this and provide the original entry where held.
Date of Response: 05/11/2026
View Response: 12014.pdf

Freedom of Information Request Reference: 12011
Date Received: 06/10/2026
Summary:
1. The number of patients placed on insulin pumps for each financial year since ring fencing was introduced. 2. The current, and estimated number of patients to be placed on insulin pumps for financial year 2026/2027. 3. The projection for subsequent financial years of the number of patients to be placed on insulin pumps.
Date of Response: 03/11/2026
View Response: 12011.pdf

Freedom of Information Request Reference: 12009
Date Received: 06/10/2026
Summary:
For the 4 months from May to August 2026:, how many unique patients received the following intra-vitreal treatments for any eye condition: Aflibercept (Eylea) Aflibercept (Eylea 8mg - Eylea HD) Aflibercept (Biosimilar, examples include but are not limited to Eydenzelt, Mynzepli or Vgenfli) Bevacizumab Brolucizumab Dexamethasone Faricimab Ranibizumab Fluocinolone acetonide
Date of Response: 03/11/2026
View Response: 12009.pdf

Freedom of Information Request Reference: 12008
Date Received: 05/10/2026
Summary:
Please could you provide the total number of consultations at the Wester Hailes Walk-in Clinic, broken down by a) patient’s GP Practice of origin and b) patient’s postcode sector e.g. EH10, EH11 etc, covering the last 6 months. Please provide all tabular data in a machine-readable electronic format such as Microsoft Excel (.xlsx) or Comma-Separated Values (.csv), rather than a flattened PDF document, if possible.
Date of Response: 03/11/2026
View Response: 12008.pdf

Freedom of Information Request Reference: 12006
Date Received: 05/10/2026
Summary:
1. How much did the organisation spend on agency (non-contract) staff and internal bank staff for the financial year 25/26 (April 2025 - March 2026)? Please fill in the spend in the table below for each staffing group and total. 2. How much did the organisation spend on Waiting List Initiative (WLI) and Overtime payments to staff (WLI payments refers to any sessional payments made for additional time worked under a system called the Waiting List Initiative, used by trusts to reduce waiting lists and meet government targets. Overtime payments are defined as any payment for additional time beyond the standard FTE for the grade). Please fill in the spend and number of sessions/hours in the below table for each staffing group and total.
Date of Response: 03/11/2026
View Response: 12006.pdf

Freedom of Information Request Reference: 12005
Date Received: 05/10/2026
Summary:
1/ the total number of unfilled GP out of hours shifts in 2023, 2024, 2025 and 2026 to date? 2/ the number of instances when no out of hours service was available in any area in in 2023, 2024, 2025 and 2026 to date, along with details of the date and area?
Date of Response: 03/11/2026
View Response: 12005.pdf

Freedom of Information Request Reference: 12004
Date Received: 05/10/2026
Summary:
I am writing regarding medical care I received in 2025 while living in the health board area. I require documentation for an overseas insurer/legal representative involved in a civil case. I am aware that as a resident, my care was funded via general taxation and did not produce an invoice. However, the foreign insurer requires a formal declaration of the "notional" or commercial value of the services. Can your overseas visitor or finance team provide a short letter confirming the standard non-resident tariff rates or internal reference costs for the following 2025 services? 1. A standard General Practitioner (GP) consultation. 2. A plain-film X-ray performed at Western General Hospital.
Date of Response: 03/11/2026
View Response: 12004.pdf

Freedom of Information Request Reference: 12002
Date Received: 05/10/2026
Summary:
I request the following recorded information for each financial year from 2021/22 to 2025/26 and monthly for the current financial year: 1. The total spending on agency nursing/midwifery staff and total spending on agency medical and dental staff. a. The total spending on internal bank staff for these same groups. b. The number of agency shifts worked by each group. 2. The highest hourly rate (or per shift rate) paid to an agency for any nursing and any medical shift in each period, and the number of shifts booked above any applicable national price cap/framework rate. 3. Any record of shifts that were agency filled due to bank requests going unfulfilled. 4. Any reports/papers on the board's agency spending presented to its finance/staff governance/audit committees.
Date of Response: 05/11/2026
View Response: 12002.pdf

Freedom of Information Request Reference: 12001
Date Received: 05/10/2026
Summary:
I request the following recorded information for the period 1 April 2024 to the date of this request: 1. Copies of all reports made to your board and any of its committees by individuals with lead clinical professional responsibility under the boards procedure for reporting on compliance with its duties under the Health and Care (Staffing) (Scotland) Act 2019. a. Please include every quarterly report in this period. If any quarter has no report, please say so. 2. Any entry on the corporate/divisional risk register that refers to unfilled shifts/the inability to staff wards safely. a. Please include the risk description, risk rating, date raised, and any record of changes in rating/or of the risk being closed or downgraded. 3. The number of times the boards real-time staffing and risk escalation procedures were used, by month, and for each occasion: the hospital site, outcome, and whether the risk was recorded as resolved. a. If not recorded centrally, please state this and where it is recorded instead. 4. The number of incident reports (Datix/equivalent) wherein inadequate staffing/unfilled shifts were recorded as a contributory factor, by month and by severity category. 5. Any report/paper/briefing from your board or its committees that analyses unfilled shifts and/or their effect on patient care. a. Please provide the papers themselves, and not summaries. 6. Any correspondence between the board and the Scottish Government, or, Healthcare Improvement Scotland, wherein unfilled shifts/staffing shortalls were raised as a concern.
Date of Response: 02/11/2026
View Response: 12001.pdf

Freedom of Information Request Reference: 12000
Date Received: 02/10/2026
Summary:
1. Digital Dictation ● Name of supplier & product ● Number of user licences ● Procurement method (e.g., framework) ● Contract start date ● Contract expiry date (please specify fixed end date vs option to extend/rolling contract) ● Total contract value (if available) ● Integration with PAS/EPR (please specify if outbound only – e.g., patient demographics, clinic work list – or outbound and inbound, e.g., document return) ● Key internal stakeholder role/title ● Desired features not currently delivered (optional) 2. Outsourced Transcription ● Name of supplier & product ● Procurement method (e.g., framework) ● Contract start date ● Average monthly volume of letters (if available) ● Average monthly volume of lines (if available) ● Total contract value (if available) ● Key internal stakeholder role/title ● Desired features not currently delivered (optional) 3. Speech Recognition ● Name of supplier & product ● Number of user licences ● Procurement method (e.g., framework) ● Contract start date ● Contract expiry date (please specify fixed end date vs option to extend/rolling contract) ● Total contract value (if available) ● Integration with PAS/EPR (please specify if outbound only – e.g., patient demographics, clinic work list – or outbound and inbound, e.g., document return) ● Key internal stakeholder role/title ● Desired features not currently delivered (optional) 4. Ambient AI Scribe ● Name of supplier & product ● Number of user licences ● Procurement method (e.g., framework) ● Contract start date ● Contract expiry date (please specify fixed end date vs option to extend/rolling contract) ● Total contract value (if available) ● Integration with PAS/EPR (please specify if outbound only – e.g., patient demographics, clinic work list – or outbound and inbound, e.g., document return) ● Pilot stage (if applicable, please specify supplier, pilot duration, and scope) ● Key internal stakeholder role/title ● Desired features not currently delivered (optional) 5. Video Consultation ● Name of supplier & product ● Number of user licences ● Procurement method (e.g., framework) ● Contract start date ● Contract expiry date (please specify fixed end date vs option to extend/rolling contract) ● Total contract value (if available) ● Integration with PAS/EPR (please specify if outbound only – e.g., patient demographics, clinic work list – or outbound and inbound, e.g., document return) ● Key internal stakeholder role/title ● Desired features not currently delivered (optional) ● Average number of video appointments per month/year ● % of virtual/remote consultations conducted using video vs telephone 6. Health Information Systems Name of supplier & product of the following HIS: ● PAS (Patient Administration System) ● EPR (Electronic Patient Record) ● eDMS (Electronic Document Management System) ● RIS (Radiology Information System) ● LIMS (Laboratory Information Management System) ● e-Correspondence (e.g. Docman) ● Hybrid Mail (e.g. Synertec, Healthcare Communications) ● Patient Portal (e.g. Patient Knows Best)
Date of Response: 03/11/2026
View Response: 12000.pdf

Freedom of Information Request Reference: 11998
Date Received: 02/10/2026
Summary:
Under the Freedom of Information (Scotland) Act 2002, please provide the following information about adult (age 18+) ADHD assessment services in your board area. If information is held by a Health and Social Care Partnership or another body on your behalf, please include it or tell me where to direct the request. Part A – Current waiting list 1. The number of adults currently waiting for an ADHD assessment, as at the most recent date available (please state the date). 2. That number broken down by length of wait from referral: under 12 weeks; 12–52 weeks; 1–2 years; over 2 years. 3. The median and longest current wait, in weeks. Part B – Activity 4. The number of adult ADHD assessments completed in each calendar year 2023, 2024 and 2025. 5. Of those, the number that resulted in an ADHD diagnosis. Part C – Referrals and acceptance criteria 6. The number of adult ADHD referrals received, accepted onto the waiting list, and rejected or redirected, in each calendar year 2023, 2024 and 2025. 7. For rejected or redirected referrals, the main reasons recorded, with the number for each reason where held. 8. Whether the board has, or has had at any time since 1 January 2020, criteria limiting which adults are accepted for ADHD assessment (for example a requirement for a co-occurring mental health condition, a level of risk, or a functional impairment threshold). If so, please provide a copy of each version of the criteria and the dates each applied. Part D – Equality impact assessment 9. Whether an Equality Impact Assessment was carried out for any criteria in question 8 or for decisions on the capacity of the adult ADHD service. If so, please provide a copy. Part E – Waiting time standards 10. Whether adult ADHD assessment waits are measured against any waiting time standard or target, local or national, and if so which.
Date of Response: 03/11/2026
View Response: 11998.pdf

Freedom of Information Request Reference: 11995
Date Received: 02/10/2026
Summary:
How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs: •Adalimumab - Humira •Adalimumab Biosimilar •Etrasimod •Filgotinib •Golimumab - Simponi •Golimumab Biosimilar •Infliximab - Remicade •Infliximab Biosimilar •Mirikizumab •Ozanimod •Risankizumab •Tofacitinib •Upadacitinib •Ustekinumab - Stelara •Ustekinumab Biosimilar •Vedolizumab •Guselkumab
Date of Response: 03/11/2026
View Response: 11995.pdf

Freedom of Information Request Reference: 11991
Date Received: 01/10/2026
Summary:
Can I request, broken down by the calendar years 2021, 2022, 2023, 2024, 2025 and 2026 (most recent data): 1. How many medical shifts have gone unfilled after being put out for locum cover, broken down by speciality, position (e.g. consultant, resident doctor) and location (e.g. ward, unit, hospital). 2. How many nursing and midwifery shifts have gone unfilled after being put out for bank and agency cover, broken down by band and location (e.g. ward, unit, hospital). 3. How many allied health professional shifts have gone unfilled after being put out for bank and agency cover, broken down by role (e.g. diagnostic radiographer, occupational therapist, physiotherapist) and location (e.g. ward, unit, hospital).
Date of Response: 03/11/2026
View Response: 11991.pdf

Freedom of Information Request Reference: 11988
Date Received: 01/10/2026
Summary:
I would like to request the following information regarding diagnostic imaging equipment (MRI and CT), staffing, and spending within your health board: 1. The total number of breakdowns and technical maintenance incidents that resulted in more than 24 hours of scanner downtime during the calendar years 2023, 2024, 2025, and 2026 to date. 2. The current number of vacant Full-Time Equivalent (FTE) positions for a) Consultant Clinical Radiologists, and b) Diagnostic Radiographers (specifically those trained in MRI/CT). 3. The total financial spend by your health board on outsourcing scan interpretations/reporting to private companies or external groups during the calendar years 2023, 2024, 2025, and 2026 to date. 4. The total financial spend by your health board on agency staff to operate MRI and CT scanners during the calendar years 2023, 2024, 2025, and 2026 to date. 5. The total number of scans (MRI and CT) that were referred to private healthcare facilities due to internal NHS capacity limitations during the calendar years 2023, 2024, 2025 and 2026 to date.
Date of Response: 03/11/2026
View Response: 11988.pdf

Freedom of Information Request Reference: 11987
Date Received: 01/10/2026
Summary:
I would like to request the following information regarding diagnostic imaging equipment within your health board: 1. How many a) MRI scanners, b) CT scanners, c) X-Ray machines does your health board have? 2. What is the oldest MRI scanner currently in use in your Health Board? 3. What is the oldest CT scanner currently in use in your Health Board? 4. What is the oldest X-Ray machine currently in use in your Health Board? 5. How many MRI scanners currently in use in your Health Board are a) over 10 years old; b) over 15 years old 6. How many CT scanners currently in use in your Health Board are a) over 10 years old; b) over 15 years old 7. How many X-Ray machines currently in use in your Health Board are a) over 10 years old; b) over 15 years old
Date of Response: 03/11/2026
View Response: 11987.pdf

Freedom of Information Request Reference: 11986
Date Received: 01/10/2026
Summary:
Please could you provide the following information for each of your current technology providers: 1. Current Provider 2. Contract End Date 3. Estimated Annual Spend - Wide Area Network Connectivity - Dark Fibre Services - Ethernet (Point to point) Connectivity - Broadband/FTTP/SOGEA services - Point-to-Cloud/Internet access services - WAN Professional Services - Local Area Network Connectivity - Wireless Local Area Network Connectivity - LAN/WLAN Managed Services - LAN/WLAN Maintenance Services - LAN/WLAN Professional Services - Data Centre Networking - Compute/Storage/Virtualisation Technology - Data Centre Managed Services - Data Centre Maintenance Services - Data Centre Professional Services - Cloud Solutions - Private Cloud - Public Cloud - Co-Location or Hosted Services - Unified Communications - Contact Centre - SIP Telephony - Telephony/Contact centre Managed Services - Telephony/Contact centre Maintained Services - Telephony/Contact centre Professional Services - Mobile Voice and Data Services - Mobile Devices (handsets and tablets) - Data only SIM or machine to machine/IoT - Mobility Managed Services - MDM Services - UEM services
Date of Response: 02/11/2026
View Response: 11986.pdf

Freedom of Information Request Reference: 11984
Date Received: 30/09/2026
Summary:
I am making a Freedom of Information request regarding complaints, investigations and incidents in which staff shortages, understaffing or inadequate staffing levels were identified as a contributing factor to a patient’s death. Please provide the following information for the five most recent complete financial years: 1. The number of complaints received in which staff shortages, understaffing or inadequate staffing levels were alleged or identified as contributing to the death of a patient. 2. Of these complaints, the number where an investigation concluded that staffing shortages were identified as a contributing factor to the patient’s death. 3. The number of deaths investigated through an incident investigation, serious incident investigation, mortality review or equivalent process where staffing shortages were identified as a contributing factor. 4. Where available, please provide a year-by-year breakdown. 5. Where available, please provide the relevant department or service involved, such as: * Emergency Department/A&E * Inpatient wards * Maternity * Paediatrics * Mental health * Community services * Other 6. Where available, please state how many of these cases resulted in: * A formal investigation * A finding of failings in staffing levels * Recommendations for changes to staffing levels * A referral to an external organisation or regulator * A coroner’s involvement
Date of Response: 02/11/2026
View Response: 11984.pdf

Freedom of Information Request Reference: 11980
Date Received: 29/09/2026
Summary:
Please provide the following information for the consultation period: 1. Whether IP address information, IP logs, device identifiers, audit logs or other technical metadata associated with electronically submitted questionnaires was retained. 2. If such information was retained, whether NHS Lothian carried out any checks or analysis to identify: • multiple questionnaire submissions originating from the same IP address • unusually high numbers of submissions from the same IP address or network • other indicators of duplicate, coordinated or potentially fraudulent submissions. 3. The number of questionnaire submissions that originated from IP addresses which were also associated with one or more other submissions. 4. The number of distinct IP addresses from which more than one questionnaire was submitted, broken down into: • 2 submissions • 3-5 submissions • 6-10 submissions • 11-20 submissions • more than 20 submissions 5. Whether any submissions were flagged, investigated, discounted, excluded or otherwise treated differently because of concerns regarding duplicate, coordinated or potentially fraudulent responses. 6. Any policies, procedures, guidance or criteria used to verify the authenticity of questionnaire responses
Date of Response: 05/11/2026
View Response: 11980.pdf

Freedom of Information Request Reference: 11979
Date Received: 29/09/2026
Summary:
Please confirm whether your organisation currently uses Dragon Medical One (DMO) or any other Nuance/Microsoft clinical speech-recognition solution. If so, please provide the following: 1. The number of DMO (or equivalent Nuance/Microsoft) licences purchased. 2. The number of active/licensed users. 3. The name of the current supplier or reseller. 4. The current annual contract or licence value. 5. The contract start date. 6. The contract end or renewal date. 7. Details of any available extension options (e.g. number and length of extension periods). 8. The name of the associated EPR/EHR or principal clinical system, where this is held as part of the contract information. 9. Whether a replacement or renewal procurement is already planned and, if so, the anticipated date (month/year is sufficient).
Date of Response: 02/11/2026
View Response: 11979.pdf

Freedom of Information Request Reference: 11971
Date Received: 28/09/2026
Summary:
I would like to request copies of policies and/or guidance from the health board to psychiatrists it employs relating to email communication with patients and family members. I request copies of policies governing from April 2025 to the date on which this request is processed.
Date of Response: 02/11/2026
View Response: 11971.pdf

Freedom of Information Request Reference: 11963
Date Received: 24/09/2026
Summary:
To request information relating to surrogacy arrangements and the care of surrogate mothers, babies born through surrogacy, and intended parents within your health board. For each calendar year from 1 January 2018 to the date of this request, please provide: 1. The number of pregnancies and/or births involving a surrogate mother recorded by the health board, where this can be identified from existing records or structured data. 2. The number of clinical incident reports, including Datix or equivalent incident reports, which relate to surrogacy arrangements. 3. The number of formal complaints relating to the maternity, neonatal or postnatal care of: o a surrogate mother; o a baby born through surrogacy; or o intended parent(s). 4. The number of safeguarding referrals or safeguarding concerns recorded in connection with a surrogacy arrangement. 5. The number of occasions on which staff sought internal or external legal advice in relation to a surrogacy arrangement. For questions 2–5, where this information is held and can be provided without identifying individuals, please also provide the broad nature of the issue, the service or department involved, and the outcome or resolution. I am particularly interested in incidents, complaints or requests for advice concerning: • consent to medical treatment for a newborn; • disclosure of confidential information to intended parents; • discharge of a baby into the care of intended parents; • legal parenthood or birth registration; • disagreements between a surrogate and intended parent(s); • safeguarding concerns; • access to maternity or neonatal wards; • the involvement of intended parents in maternity or neonatal care. Please also provide: 6. A copy of the health board’s current policy, guidance, protocol or standard operating procedure relating to surrogacy, together with the previous version immediately preceding it, if one exists. 7. The date on which the current policy or guidance was approved, the date of its most recent review, and the date on which it is next due to be reviewed. 8. Details of any training, briefing or guidance provided to maternity, neonatal or other relevant staff specifically concerning surrogacy since 1 January 2018. Where held, please provide the date, title or description of the training and the number of staff who attended or completed it. If the health board does not record surrogacy as a specific field or code within its maternity, incident-reporting, complaints or safeguarding systems, please state this. In that event, I would also be grateful if you could identify: • the relevant system or systems used; • whether surrogacy can be identified through any structured field, code or category; • and whether records containing terms such as “surrogacy”, “surrogate”, “intended parent” or “parental order” can be searched within those systems. I am seeking statistical and administrative information and do not require any patient-identifiable information.
Date of Response: 05/11/2026
View Response: 11963.pdf

Freedom of Information Request Reference: 11959
Date Received: 23/09/2026
Summary:
To ask how many cases your health board has recorded of staff members viewing patient medical records without the appropriate permission. Could this be broken down by the following years... 2021/22 2022/23 2023/24 2024/25 2025/26
Date of Response: 03/11/2026
View Response: 11959.pdf

Carer Positive Icon
Awards Aware Icon
We are a Living wage Employer Icon
Duke of Edinburgh's Award Logo
Young Person's Guaranteed Employer Logo
Scottish Top Employers Logo
Disability Confident Employer Logo

 
NHS Lothian Charity Logo
Scottish Registered Charity No: SC007342
The official charity of NHS Lothian.
From the everyday to the transformational, we support NHS Lothian to excel for all the communities it serves: patients, families, carers and staff.
Making healthcare better, together.
Find out more about NHS Lothian Charity
Donate